[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"follicular-lymphoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:follicular-lymphoma":28},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,85,0,25,[9,42,75,127,151,187,213,237,262,279,302,331,364,386,423,456,479,503,529,552,577,601,629,649,672],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100641666","phase-2-a-clinical-trial-of-mk-1045-and-rituximab-in-people-with-follicular-lymphoma-mk-1045-007-100641666",false,"NCT07634471","A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)","A Phase 2\u002F3 Randomized, Open-label Study of MK-1045 in Combination With Rituximab in Participants With 1L Follicular Lymphoma","Inclusion Criteria:\n\n* Has biopsy-proven, previously untreated, histologically confirmed cluster of differentiation (CD)19-positive and CD20-positive classical follicular lymphoma (FL), with Ann Arbor Stage II-IV disease and a Follicular Lymphoma International Prognostic Index (FLIPI) score of 2-5.\n* Has radiographically measurable disease per the Lugano Response Criteria.\n* Has provided a newly obtained core or excisional biopsy or archival tissue of a tumor lesion not previously irradiated.\n* If human immunodeficiency virus (HIV)-positive, has well-controlled HIV on antiretroviral therapy (ART).\n* If hepatitis B surface antigen (HBsAg)-positive, has undetectable hepatitis B virus (HBV) viral load and has received HBV antiviral therapy for at least 4 weeks and will continue it.\n* If history of hepatitis C virus (HCV) infection, has undetectable HCV viral load.\n\nExclusion Criteria:\n\n* Has received prior systemic anticancer therapy or radiotherapy for FL.\n* Has follicular large B-cell lymphoma or any other subtype of FL other than classical FL.\n* Has FL that has transformed into a more aggressive type of lymphoma.\n* History or presence of clinically relevant central nervous system (CNS) diseases.\n* Has history of serious cardiovascular and cerebrovascular diseases.\n* Is HIV-infected with a history of Kaposi's sarcoma and\u002For Multicentric Castleman's Disease.\n* Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention.\n* Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy.\n* Has a known additional malignancy that is progressing or has required active treatment within the past 3 years.\n* Has known active CNS lymphoma or involvement.\n* Has an active autoimmune disease that has required systemic treatment in the past 2 years.\n* Has active infection requiring systemic therapy.\n* Has chronic liver disease, including liver cirrhosis of Child-Pugh class B or C.\n* Has not adequately recovered from major surgery or has ongoing surgical complications.","ALL","18 Years",{"count":20,"type":21},960,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE2","PHASE3","Researchers are looking for new ways to treat follicular lymphoma (FL). A standard (usual) treatment for FL includes a targeted therapy called rituximab and chemotherapy. In this study, researchers want to learn if giving a study medicine called MK-1045 and rituximab can treat FL. MK-1045 is a type of treatment called immunotherapy.\n\nThe goals of this study are to learn:\n\n* About the safety of MK-1045 and rituximab, and if people tolerate them when given together\n* If people who receive MK-1045 and rituximab have the cancer go away\n* If people who receive MK-1045 and rituximab live longer without their cancer getting worse compared to those who receive standard treatment (rituximab and chemotherapy)",[28],"Follicular Lymphoma","RECRUITING","2026-07-01",{"date":32,"type":33},"2026-07-02","ACTUAL",{"date":35,"type":21},"2026-07-06",{"date":37,"type":21},"2035-07-23",{"name":39,"class":40},"Merck Sharp & Dohme LLC","INDUSTRY",8,{"id":43,"slug":44,"hasResults":12,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":22,"phases":50,"briefSummary":52,"conditions":53,"keywords":62,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":74},"100582251","combating-cancer-related-fatigue-a-personalized-supportive-care-program-100582251","NCT06860880","Combating Cancer-Related Fatigue: A Personalized Supportive Care Program","In order to participate in this study a subject must meet all of the eligibility criteria outlined below.\n\nInclusion Criteria:\n\n* Written informed consent was obtained to participate in the study and HIPAA authorization for the release of personal health information.\n* Subjects are willing and able to comply with study procedures based on the judgment of the investigator.\n* Age ≥ 18 years at the time of consent.\n* Confirmed diagnosis of indolent lymphoma, Waldenström's Macroglobulinemia, or Cutaneous T Cell Lymphoma.\n* Significant symptoms of fatigue, as defined by PROMIS Fatigue score \\>50.\n\nExclusion Criteria:\n\n* Other co-existing malignancies.\n* Significant cognitive impairment as defined by Mini-Cog score 0-2 (out of 5) that would prevent understanding of assessments or interventions.\n* Unstable or serious illness (e.g., unstable cardiac arrhythmia, severe anemia\u002Fthrombocytopenia) that would prevent safe participation in an exercise regimen, per the discretion of the treating physician.\n* Individuals who are not able to consume an oral diet, due to swallowing difficulties or other reasons, as this might interfere with the nutritional intervention",{"count":49,"type":21},40,[51],"NA","This health services study will assess a multidisciplinary intervention program directed at fatigue mitigation among patients diagnosed with indolent lymphomas. Specifically, 30 subjects with chronic lymphocytic leukemia\u002Fsmall lymphocytic lymphoma (CLL\u002FSLL) and 10 subjects with Follicular Lymphoma (FL), marginal zone lymphoma (MZL), lymphoplasmacytic lymphoma (LPL), Waldenström's Macroglobulinemia, or Cutaneous T Cell Lymphoma (CTCL) will be included.",[54,55,56,57,28,58,59,60,61],"Indolent Lymphomas","Lymphoma","Chronic Lymphocytic Leukemia","Small Lymphocytic Lymphoma","Marginal Zone Lymphoma","Lymphoplasmacytic Lymphoma","Waldenstrom Macroglobulinemia","Cutaneous T Cell Lymphoma",[63,64],"exercise","dietary intervention","2026-06-29",{"date":30,"type":33},{"date":68,"type":33},"2025-06-03",{"date":70,"type":21},"2026-12-31",{"name":72,"class":73},"UNC Lineberger Comprehensive Cancer Center","OTHER",1,{"id":76,"slug":77,"hasResults":12,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":22,"phases":85,"briefSummary":86,"conditions":87,"keywords":111,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":74},"100309946","phase-2-myeloablative-allo-hsct-with-related-or-unrelated-donor-for-heme-disorders-100309946","NCT03314974","Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders","Myeloablative Allogeneic Hematopoietic Cell Transplantation Using a Related or Unrelated Donor for the Treatment of Hematological Diseases","-Inclusion Criteria:\n\n* Age: ≤ 60 years of age\n* Performance Status: Karnofsky ≥ 70%, Lansky play score ≥ 70\n* Consent: Voluntary written consent (adult or legally authorized representative; or parental\u002Fguardian)\n* Adequate Organ Function:\n\n  * Renal: Creatinine \\\u003C2x upper limit of normal. Patients above this limit must have creatinine clearance ≥ 40 ml\u002Fmin\u002F1.73m2 as determined by an age-appropriate method, such as cystatin C GFR.\n  * Hepatic: Bilirubin, AST, alkaline phosphatase \\\u003C4 times the upper limit of institutional normal\n  * Pulmonary: Diffusion capacity of oxygen, corrected for hemoglobin, \\> 50% of predicted. For pediatric patients not able to undergo PFTs or diffusion testing: O2 sat of \\>95% on room air\n  * Cardiac: Absence of decompensated congestive heart failure, or uncontrolled arrhythmia and left ventricular ejection fraction \\> 45%. For children not able to cooperate with MUGA or echocardiography, such should be clearly stated in the physician's documentation\n  * HIV Status: HIV infection with undetectable viral load. All HIV+ patients must be evaluated by Infectious Disease (ID) and a HIV management plan establish prior to transplantation\n\nOther Inclusion Criteria:\n\n* Women of child bearing potential and sexually active males with partners of child bearing potential must agree to use adequate birth control for the duration of treatment.\n* Donor Availability: Patients considered for transplantation must have a sufficient graft as based on current criteria of the University of Minnesota Blood and Marrow Transplantation Program\n* Eligible Diseases and Status: Patients are eligible unless their treatment is to be guided by a higher priority protocol.\n* Acute Leukemias: Must be in remission by morphology (≤5% blasts). Also a small percentage of blasts that is equivocal between marrow regeneration vs. early relapse are acceptable provided there are no associated cytogenetic markers consistent with relapse.\n* Acute Myeloid Leukemia (AML) and related precursor neoplasms: 2nd or greater complete remission (CR); first complete remission (CR1) in patients \\> 60 years old; CR1 in ≤ 60 years old that is NOT considered as favorable-risk.\n* Favorable risk AML is defined as having one of the following:\n\n  * t(8,21) without cKIT mutation\n  * inv(16) or t(16;16) without cKIT mutation\n  * Normal karyotype with mutated NPM1 and wild type FLT-ITD\n  * Normal karyotype with double mutated CEBPA\n  * Acute prolymphocytic leukemia (APL) in first molecular remission at the end of consolidation\n* Very high risk pediatric patients with AML: Patients \\\u003C21 years, however, are eligible with (M2 marrow) with \\\u003C 25% blasts in marrow after having failed one or more cycles of chemotherapy.\n* Acute lymphoblastic leukemia (ALL)\u002Flymphoma: second or greater CR; CR1 unable to tolerate consolidation chemotherapy due to chemotherapy-related toxicities; CR1 high-risk ALL.\n* High risk ALL is defined as having one of the following:\n\n  * Evidence of high risk cytogenetics, e.g. t(9;22), t(1;19), t(4;11), other MLL rearrangements, IKZF1\n  * 30 years of age or older at diagnosis\n  * White blood cell counts of greater than 30,000\u002FmcL (B-ALL) or greater than 100,000\u002FmcL (T-ALL) at diagnosis\n  * CNS leukemia involvement during the course of disease\n  * Slow cytologic response (\\>10% lymphoblasts in bone marrow on Day 14 of induction therapy)\n  * Evidence of persistent immonophenotypic or molecular minimal residual disease (MRD) at the end of induction and consolidation therapy\n* Very high risk pediatric patients with ALL: patients \\\u003C21 years are also considered high risk CR1 if they had M2 or M3 marrow at day 42 from the initiation of induction or M3 marrow at the end of induction. They are eligible once they achieve a complete remission.\n* Chronic Myelogenous Leukemia excluding refractory blast crisis: To be eligible in first chronic phase (CP1) patient must have failed or be intolerant to one or more tyrosine kinase inhibitors.\n* Plasma Cell Leukemia after initial therapy, in patients who have achieved at least a partial remission\n* Myeloproliferative Neoplasms\u002FMyelofibrosis, either primary as a result of polycythemia vera or essential thrombocythemia, with disease risk of intermediate or high-risk according to DIPSS criteria. Blasts must be \\\u003C10% by bone marrow aspirate morphology.\n* Myelodysplasia (MDS) IPSS INT-2 or High Risk (i.e. RAEB, RAEBt) or Refractory Anemia with severe pancytopenia, transfusion dependence, or high risk cytogenetics or molecular features. Blasts must be \\\u003C 10% by a representative bone marrow aspirate morphology.\n* Chronic Lymphocytic Leukemia\u002FSmall Lymphocytic Lymphoma (CLL\u002FSLL), Marginal Zone B-Cell Lymphoma or Follicular Lymphoma are eligible if there was disease progression\u002Frelapse within 12 of achieving a partial or complete remission. Patients who had remissions lasting \\> 12 months, are eligible after at least two prior therapies. Patients with bulky disease (nodal mass greater than 5 cm) should be considered for debulking chemotherapy before transplant.\n* Lymphoplasmacytic Lymphoma, Mantle-Cell Lymphoma, Prolymphocytic Leukemia are eligible after initial therapy in CR1+ or PR1+.\n* Diffuse large Cell NHL \\> CR\u002F\\> PR: Patients in CR\u002FPR with initial short remission (\\\u003C6 months) are eligible, or those who have failed\u002For are not eligible for autologous transplant.\n* Lymphoblastic Lymphoma, Burkitt's Lymphoma, and other high-grade NHL after initial therapy if stage III\u002FIV in CR1\u002FPR1 or after progression if stage I\u002FII \\\u003C 1 year.\n* Multiple Myeloma beyond PR2: Patients with chromosome 13 abnormalities, first response lasting less than 6 months, or β-2 microglobulin \\> 3 mg\u002FL, may be considered for this protocol after initial therapy.\n* Juvenile myelomonocytic leukemia\n* Biphenotypic\u002FUndifferentiated\u002FProlymphocytic Leukemias in first or subsequent CR.\n* MRD positive leukemia (AML, ALL or accelerated\u002Fblast phase CML). Selected patients in morphologic CR, but with positive immunophenotypic (flow cytometry) or molecular evidence of MRD may be eligible if recent chemotherapy has not resulted in MRD negative status.\n* Natural Killer Cell Malignancies\n* Acquired Bone Marrow Failure Syndromes except for Fanconi Anemia or Dyskeratosis Congenita\n* Other Leukemia Subtypes: A major effort in the field of hematology is to identify patients who are of high risk for treatment failure so that patients can be appropriately stratified to either more (or less) intensive therapy. This effort is continually ongoing and retrospective studies identify new disease features or characteristics that are associated with treatment outcomes. Therefore, if new features are identified after the writing of this protocol, patients can be enrolled with the approval of two members of the study committee.\n\nExclusion Criteria:\n\n* Chemotherapy refractory large cell and high grade NHL (i.e., progressive disease after \\> 2 salvage regimens)\n* CML in blast crisis\n* Large cell lymphoma, mantle cell lymphoma and Hodgkin disease that is progressing on salvage therapy.\n* Evidence of progressive disease by imaging modalities or biopsy - persistent PET activity, though possibly related to lymphoma, is not an exclusion criterion in the absence of CT changes indicating progression.\n* Active central nervous system malignancy\n* if ≤ 18 years old, prior myeloablative transplant within the last 6 months. If \\>18 years old prior myeloablative allotransplant or autologous transplant\n* Active HIV infection or known HIV positive serology\n* active uncontrolled infection\n* Pregnant or breastfeeding. The agents used in this study include Pregnancy Category D: known to cause harm to a fetus. Females of childbearing potential must have a negative pregnancy test prior to starting therapy.","60 Years",{"count":84,"type":21},300,[24],"This is a Phase II study of allogeneic hematopoietic stem cell transplant (HCT) using a myeloablative preparative regimen (of either total body irradiation (TBI); or, fludarabine\u002Fbusulfan for patients unable to receive further radiation). followed by a post-transplant graft-versus-host disease (GVHD) prophylaxis regimen of post-transplant cyclophosphamide (PTCy), tacrolimus (Tac), and mycophenolate mofetil (MMF).",[88,89,90,55,91,92,93,94,95,96,97,56,57,98,28,59,99,100,101,102,103,104,105,106,107,108,109,110],"Acute Leukemia","Acute Myeloid Leukemia","Acute Lymphoblastic Leukemia","Chronic Myelogenous Leukemia","Plasma Cell Leukemia","Myeloproliferative Neoplasms","Myelofibrosis","Myelodysplasia","Refractory Anemia","High Risk Anemia","Marginal Zone B-Cell Lymphoma","Mantle-Cell Lymphoma","Prolymphocytic Leukemia","Diffuse Large Cell Non Hodgkins Lymphoma","Lymphoblastic Lymphoma","Burkitt Lymphoma","High Grade Non-Hodgkin's Lymphoma, Adult","Multiple Myeloma","Juvenile Myelomonocytic Leukemia","Biphenotypic\u002FUndifferentiated\u002FProlymphocytic Leukemias","MRD Positive Leukemia","Natural Killer Cell Malignancies","Acquired Bone Marrow Failure Syndromes",[112,17,113,114,115,116,117],"AML","MDS","NHL","CLL","CML","SLL","2026-06-23",{"date":120,"type":33},"2026-06-25",{"date":122,"type":33},"2018-03-30",{"date":124,"type":21},"2028-06-10",{"name":126,"class":73},"Masonic Cancer Center, University of Minnesota",{"id":128,"slug":129,"hasResults":12,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":4,"eligibilityCriteria":133,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":134,"targetDuration":4,"studyType":22,"phases":136,"briefSummary":138,"conditions":139,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":150},"100610381","phase-1-a-study-of-ly4584180-in-adult-participants-with-previously-treated-blood-cancers-100610381","NCT07226843","A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers","NOVA-BCL6-1, A First-in-Human, Multicenter Phase 1a\u002F1b Study to Investigate Safety, Tolerability, Pharmacokinetics, and Efficacy of LY4584180 in Adult Participants With Previously Treated Hematologic Malignancies","Inclusion Criteria:\n\n* Has been treated for the following blood cancers and has received at least 2 prior lines of systemic therapy or not eligible for available therapy:\n\n  * Diffuse large B-cell lymphoma - not otherwise specified\n  * High-grade B-cell lymphoma\n  * Diffuse large B-cell lymphoma - transformed from indolent lymphomas\n  * Follicular large B-cell lymphoma\n  * Follicular lymphoma\n  * Other non-Hodgkin lymphoma\n* Has measurable disease\n* Has discontinued all previous treatments for cancer and has recovered from the immediate effects of therapy\n\nExclusion Criteria:\n\n* Has an active second cancer\n* Has known central nervous system (CNS) involvement by systemic lymphoma. Patients with previous treatment for CNS involvement who are neurologically stable and without evidence of active CNS disease may be eligible and enrolled if a compelling clinical rationale is provided by the Investigator and with documented Sponsor approval.\n* Has known Cytomegalovirus infection. Participants with negative status are eligible\n* Has known hepatitis B or C infection or uncontrolled HIV\n* Has known significant heart disease",{"count":135,"type":21},460,[137],"PHASE1","The main purpose of this study is to evaluate safety and efficacy, and measure how much LY4584180 gets into the bloodstream and how long it takes the body to eliminate it in patients with previously treated blood cancers. For each participant, the study could last about 9 months or possibly longer including screening.",[140,141,28],"Lymphoma, Non-Hodgkin's","Lymphoma, Diffuse Large B-Cell","2026-06-22",{"date":118,"type":33},{"date":145,"type":33},"2026-04-17",{"date":147,"type":21},"2030-02",{"name":149,"class":40},"Eli Lilly and Company",46,{"id":152,"slug":153,"hasResults":12,"nctId":154,"briefTitle":155,"officialTitle":155,"acronym":156,"eligibilityCriteria":157,"healthyVolunteers":158,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":159,"targetDuration":4,"studyType":22,"phases":161,"briefSummary":162,"conditions":163,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":179,"startDateStruct":181,"completionDateStruct":182,"leadSponsor":184,"locationsCount":74},"100590778","evaluation-of-skin-tests-in-biotherapy-allergies-100590778","NCT06971848","Evaluation of Skin Tests in Biotherapy Allergies","ETCABIO","Inclusion Criteria :\n\n* Patient treated with one of the biotherapies under study (Atezolizumab 1200 mg, Nivolumab 480 mg, Obinutuzumab 100 mg, Durvalumab 1500 mg, Pembrolizumab 200 mg, Daratumumab 1800 mg, Cemiplimab 3500 mg) and who has received at least two injections of the biotherapy without suspected allergic side effects.\n* Subjects covered by or having the rights to medical care assurance\n* Written informed consent obtained from subject\n* If applicable, treatment with corticosteroids and H1 antihistamines by systemic route (IV or oral) which may be discontinued at least one week before performing the tests (Inhaled corticosteroids are allowed).\n\nExclusion Criteria:\n\n* Presence of local or diffuse dermatological lesions (e.g., psoriasis, eczema, ...) that could interfere with the interpretation of skin tests.\n* Poor understanding of the French language\n* Pregnancy, breastfeeding\n* Persons in detention by judicial or administrative decision\n* Person admitted to a health or social establishment for purposes other than research\n* Person subject to a legal protection measure",true,{"count":160,"type":21},70,[51],"Biotherapies are biological (extracted from an organism or living tissue) or biotechnological drugs used in the treatment of multiple conditions, such as autoimmune inflammatory diseases, cancers, and hematologic diseases. In recent years, these biotherapies have notably emerged in the treatment of cancers and hematologic disorders. As such, most patients with cancers or hematologic diseases will likely receive a biotherapy as part of their care pathway.\n\nThese biotherapies are associated with various side effects, including hypersensitivity or allergic reactions, which are often poorly characterized in clinical trials. These reactions manifest as symptoms without specific dermatologic or allergologic semiology (such as itching, erythema, shortness of breath, sometimes digestive issues, or discomfort, and in some cases, an anaphylactic reaction).\n\nUnlike other treatments, such as antibiotics and neuromuscular blockers, there are currently no guidelines on the concentrations to use in skin tests for biotherapies. We propose conducting prospective clinical research to scientifically establish the concentrations to be used when investigating hypersensitivity to a biotherapy, in line with best practice recommendations for drug skin testing.",[164,165,166,167,168,169,56,28,170,171,172,173,174,175,176,177],"Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck","Melanoma Neoplasms","Small Cell Bronchial Carcinomas","Bronchial Carcinoma","Pleural Mesothelioma","Hodgkin's Lymphoma","Myeloma","AL Amyloidosis","Hepatocarcinoma","Colorectal Cancer","Esophageal Squamous Cell Carcinoma","Heart Cancer","Cholangiocarcinoma","Colorectal Adenocarcinoma","2026-06-17",{"date":180,"type":33},"2026-06-18",{"date":178,"type":33},{"date":183,"type":21},"2028-07",{"name":185,"class":186},"University Hospital, Angers","OTHER_GOV",{"id":188,"slug":189,"hasResults":12,"nctId":190,"briefTitle":191,"officialTitle":192,"acronym":193,"eligibilityCriteria":194,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":195,"targetDuration":4,"studyType":22,"phases":197,"briefSummary":198,"conditions":199,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":205,"startDateStruct":206,"completionDateStruct":208,"leadSponsor":210,"locationsCount":212},"100439778","phase-1-a-dose-escalation-and-expansion-study-of-bgb-16673-in-participants-with-b-cell-malignancies-100439778","NCT05006716","A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies","A Phase 1\u002F2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies","CaDAnCe-101","Inclusion Criteria :\n\n1. Confirmed diagnosis (per World Health Organization (WHO) guidelines, unless otherwise noted) of one of the following: Marginal Zone Lymphoma (MZL), R\u002FR follicular lymphoma (FL), mantle cell lymphoma (MCL), chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL\u002FSLL), Waldenström macroglobulinemia (WM), R\u002FR diffuse large B-cell lymphoma (DLBCL), or Richter's transformation to DLBCL.\n2. Participants who have previously received a covalently-binding Bruton´s tyrosine kinase (BTK) inhibitor (BTKi) in any line of therapy must have received treatment with the BTK inhibitor for ≥ 8 weeks (unless reason for discontinuation is intolerance).\n3. For dose-finding and dose-expansion, participants who had previously received a covalently-binding BTK inhibitor as monotherapy or in combination with other anticancer agents are eligible for the study if they meet any of the following criteria: discontinued the previous BTK inhibitor due to disease progression, experienced disease progression after completing treatment with a BTK inhibitor or discontinued the BTK inhibitor due to toxicity or intolerance.\n4. Phase 2 Cohorts in R\u002FR CLL\u002FSLL, R\u002FR MCL, and R\u002FR WM only: Participants who previously received a BTKi are eligible if they had disease progression on only one regimen containing a covalent BTKi. Note: Participants may have received treatment with ≥ 2 different covalent BTKis if additional BTKis were discontinued secondary to an event other than disease progression.\n5. Measurable disease by radiographic assessment or serum IgM level (WM only)\n6. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2\n7. Participants enrolling in the dose finding phase of the study may be previously treated with a BTKi or may be naïve to BTKi therapy depending on the diagnosis and country of enrollment; participants with MCL enrolling in the expansion cohorts (Phase 2) must have been treated with a BTKi in a prior line of therapy; CLL\u002FSLL participants, in addition to being treated with a BTKi in a prior line of therapy, must also have received a Bcl-2 inhibitor in a prior line of therapy as well (Phase 2).\n\nExclusion Criteria:\n\n1. Prior malignancy (other than the disease under study) within the past 2 years, except in situ malignancies that have been curatively resected, localized breast cancer treated with curative intent with no evidence of breast active disease for more than 3 years and receiving adjuvant hormonal therapy, localized Gleason score ≤ 6 prostate cancer undergoing observation or treatment with androgen depravation, or any other cancer treated with curative intent, not on adjuvant treatment, and in the opinion of the investigator is unlikely to recur.\n2. Requires ongoing systemic treatment for any other malignancy\n3. Requires ongoing systemic (defined as ≥ 10 mg\u002Fday of prednisone or equivalent) corticosteroid treatment.\n4. Current or history of central nervous system involvement including the brain, spinal cord, leptomeninges, and cerebrospinal fluid (as documented by imaging, cytology, or biopsy) by B-cell malignancy, regardless of whether participants had received treatment for central nervous system disease\n5. Known active plasma cell neoplasm, prolymphocytic leukemia, T-cell lymphoma, Burkitt lymphoma, acquired immunodeficiency syndrome (AIDS)-related B-cell lymphoma, Castleman disease, post-transplant lymphoproliferative disorders, hairy cell leukemia, germinal center B-cell (GCB), DLBCL, EBV+ DLBCL NOS, primary DLBCL of the central nervous system (CNS), primary cutaneous DLBCL - leg type, DLBCL associated with chronic inflammation, primary mediastinal (thymic) large B-cell lymphoma, intravascular large B-cell lymphoma, ALK+ large B-cell lymphoma, primary effusion lymphoma, high-grade B-cell lymphoma with MYC and BCL2 and\u002For BCL6 rearrangements, high-grade B-cell lymphoma - NOS, B-cell lymphoma unclassifiable with features intermediate between DLBCL and classical Hodgkin lymphoma, or history of or currently suspected transformation of an indolent lymphoma to an aggressive histology (except for participants with Richter Transformation to DLBCL are eligible for Part 1a, 1c, or Phase 2 and participants with history of follicular lymphoma transforming to non-GCB DLBCL who are eligible for Part 1a, 1c, or Phase 2).\n\nNote: Other protocol defined Inclusion\u002FExclusion criteria may apply.",{"count":196,"type":21},645,[137,24],"Study consists of two main parts to explore BGB-16673 recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation and monotherapy safety expansion of selected doses, and a Phase 2 (expansion cohorts)",[200,58,28,201,202,56,57,203,204],"B-cell Malignancy","Non-Hodgkin Lymphoma","Waldenström Macroglobulinemia","Mantle Cell Lymphoma","Diffuse Large B Cell Lymphoma",{"date":180,"type":33},{"date":207,"type":33},"2021-09-13",{"date":209,"type":21},"2029-11",{"name":211,"class":40},"BeOne Medicines",127,{"id":214,"slug":215,"hasResults":12,"nctId":216,"briefTitle":217,"officialTitle":218,"acronym":4,"eligibilityCriteria":219,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":220,"targetDuration":4,"studyType":22,"phases":222,"briefSummary":223,"conditions":224,"keywords":228,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":230,"startDateStruct":231,"completionDateStruct":233,"leadSponsor":235,"locationsCount":74},"100404393","phase-1-anti-cd19-chimeric-antigen-receptor-t-cells-for-treatment-of-relapsed-or-refractory-non-hodgkin-lymphoma-100404393","NCT04545762","Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma","A Phase 1 Clinical Trial of Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma","THE DOSE ESCALATION COHORT IS CLOSED TO FURTHER ENROLLMENT.\n\nInclusion Criteria:\n\nDose expansion Cohorts:\n\nCohort B (Burkitt):\n\n1. Participants must have a diagnosis of relapsed or refractory Burkitt Lymphoma\n\n   * Participants with Burkitt lymphoma must have relapsed or failed to respond to at least 1 prior line of multiagent chemoimmunotherapy with prior exposure to both an anti-CD20 antibody agent and an anthracycline.\n   * No significant circulating disease, defined as an elevated total lymphocyte count above the upper limit of normal (ULN) due to the presence of malignant cells.\n2. Participants must have measurable disease as defined below:\n\n   * Participants with Burkitt Lymphoma must have Positron Emission Tomography (PET)-positive disease according to \"Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification\"\n\nCohort M\u002FW (Marginal\u002FWaldenström):\n\n1. Participants must have a diagnosis of relapsed or refractory Marginal Zone Lymphoma (MZL), or Lymphoplasmacytic Lymphoma (LPL)\u002FWaldenström Macroglobulinemia (WM):\n\n   o Participants with indolent lymphomas (nodal or extranodal marginal zone lymphoma, and lymphoplasmacytic lymphoma) must have relapsed after or have been refractory to ≥ 2 prior lines of multi-agent chemoimmunotherapy including prior exposure to an anti-CD20 antibody and an alkylating agent.\n2. Participants must have measurable disease as defined below:\n\n   o Participants with Marginal Zone Lymphoma or Lymphoplasmacytic Lymphoma\u002FWaldenström Macroglobulinemia: must either have PET-positive disease according to \"Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification\" or serum monoclonal immunoglobulin M (IgM) paraprotein \\> 0.5 g\u002FdL.\n3. Participants with indolent lymphoma (Marginal Zone Lymphoma or Lymphoplasmacytic Lymphoma\u002FWaldenström Macroglobulinemia) must have symptomatic disease or steady progression necessitating systemic treatment per investigator discretion.\n\nIn addition, all participants must meet the following criteria:\n\n1. CD19-positive by either immunohistochemistry or flow cytometry analysis on any biopsy. If prior anti-CD19 therapy has been administered, CD19-positivity has to be re-established on the most recent biopsy.\n2. Age ≥18 years at the time of consent.\n3. Absolute lymphocyte count \\> 100\u002FUL.\n4. Eastern Cooperative Oncology Group (ECOG) performance status \\\u003C 2.\n5. Adequate organ function, defined as:\n\n   1. Adequate bone marrow function for apheresis and lymphodepleting chemotherapy\n   2. Hemoglobin \\>8 gm\u002Fdl (transfusions allowed)\n   3. Platelets \\>50,000\u002FuL (transfusions allowed)\n   4. Absolute Neutrophil Count (ANC) \\> 500\u002FuL\n   5. alanine aminotransferase (ALT)\u002Faspartate aminotransferase (AST) \\\u003C 3 x institutional upper limit of normal (ULN) and Total bilirubin \\\u003C 1.5 mg\u002Fdl x institutional ULN, except with Gilbert's syndrome\n   6. Serum Creatinine \\\u003C 2 x the institutional ULN\n   7. Adequate cardiac function, defined as left ventricular ejection fraction (LVEF) \\> 40% as assessed by echocardiogram or multiple uptake gated acquisition (MUGA) within 3 months of screening. Repeat testing may occur at Investigator's discretion.\n6. Adequate vascular access for leukapheresis procedure (either peripheral line or surgically placed line).\n7. Women of childbearing potential (defined as all women physiologically capable of becoming pregnant) must have a negative serum or urine pregnancy test AND agree to use highly effective methods of contraception for 1 year after the last dose of anti-CD19 CAR-T cells.\n8. Males who have partners of childbearing potential must agree to use an effective barrier contraceptive method.\n9. Ability to understand a written informed consent document, and the willingness to sign it.\n\nExclusion Criteria:\n\n1. Autologous transplant within 6 weeks of planned CAR-T cell infusion.\n2. Recipient of prior CAR-T cell therapy targeting CD19 outside of this protocol.\n3. Active other malignancy, other than non-melanoma skin cancer, carcinoma in situ (e.g., cervix, bladder, or breast).\n4. Human immunodeficiency virus (HIV) seropositivity.\n5. Serologic status reflecting active hepatitis B or C infection. Participants that are positive for hepatitis B core antibody, hepatitis B surface antigen (HBsAg), or hepatitis C antibody must have a negative polymerase chain reaction (PCR) prior to enrollment. (PCR positive participants will be excluded.)\n6. Participants with uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, pulmonary abnormalities or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.\n7. Pregnant or breastfeeding women are excluded from this study because CAR-T cell therapy may be associated with the potential for teratogenic or abortifacient effects. Because there is an unknown, but potential risk for adverse events in nursing infants secondary to treatment of the mother with CAR-T cells, breastfeeding should be discontinued. These potential risks may also apply to other agents used in this study. NOTE: Women of childbearing potential must have a negative serum or urine pregnancy test.\n8. Participants with history of clinically relevant central nervous system (CNS) pathology such as epilepsy, seizure disorders, paresis, aphasia, uncontrolled cerebrovascular disease, severe brain injuries, dementia and Parkinson's disease.\n9. History of autoimmune disease (e.g., rheumatoid arthritis, systemic lupus erythematosus) with requirement of immunosuppressive medication within 6 months.\n10. Body weight \\\u003C40 kilograms(kg).\n\nEligibility for Infusion of Investigational Product:\n\nParticipants will undergo an evaluation of eligibility on day 1 prior to infusion of anti-CD19 CAR-T cell product. This eligibility criterion will include the inclusion and exclusion criteria required for enrollment with the following exceptions and additions:\n\n1. No significant laboratory abnormalities. Laboratory result abnormalities that are considered not clinically significant by the principal investigator AND are not the result of a demonstrated active infection or an active central nervous system condition.\n2. ECOG performance status \\\u003C 2\n3. No evidence of uncontrolled intercurrent illness including, but not limited to ongoing or active infection, inflammatory response, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, pulmonary abnormalities or psychiatric illness\u002Fsocial situations.\n4. No new neurologic symptoms suggestive of an active central nervous system condition, or uncontrolled CNS involvement by lymphoma.\n5. No corticosteroid use within 7 days prior to infusion (with exception of agents used for prevention of emesis during lymphodepletive chemotherapy).",{"count":221,"type":21},36,[137],"This study will assess safety and feasibility of infusing genetically modified autologous T cells transduced to express a chimeric antigen receptor targeting the B cell surface antigen Cluster of Differentiation 19 (CD19).",[225,103,203,28,59,226,204,57,227,201],"Refractory Non-Hodgkin Lymphoma","Primary Mediastinal Large B Cell Lymphoma","Transformed Lymphoma",[229],"CAR-T Therapy",{"date":142,"type":33},{"date":232,"type":33},"2020-09-11",{"date":234,"type":21},"2026-10-31",{"name":236,"class":73},"C. Babis Andreadis",{"id":238,"slug":239,"hasResults":12,"nctId":240,"briefTitle":241,"officialTitle":242,"acronym":4,"eligibilityCriteria":243,"healthyVolunteers":158,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":244,"targetDuration":4,"studyType":22,"phases":246,"briefSummary":248,"conditions":249,"keywords":251,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":254,"lastUpdatePostDateStruct":255,"startDateStruct":256,"completionDateStruct":258,"leadSponsor":260,"locationsCount":74},"100564976","early-phase-1-64cu-llp2a-for-imaging-hematologic-malignancies-100564976","NCT06636175","64Cu-LLP2A for Imaging Hematologic Malignancies","Early Phase I Evaluation of 64Cu-LLP2A for Imaging Hematologic Malignancies Part B","Inclusion Criteria Healthy Volunteer:\n\n* Adult 18 years of age or older\n* Able to give informed consent.\n* Able to comprehend and willing to follow instructions for study procedures as called for by the protocol\n* Capable of lying still and supine within the PET\u002FCT scanner for up to 75 minutes.\n* No illicit drug use or other inhaled drug use (including pharmacologic agents and illicit drugs) within the past year per self-reporting mechanisms.\n* No history of claustrophobia or other condition that has previously or would interfere with completion of protocol specified imaging sessions.\n* Not currently pregnant or nursing: Subject must be surgically sterile (has had a documented bilateral oophorectomy and\u002For documented hysterectomy), post-menopausal (cessation of menses for more than 1 year), non-lactating, or of childbearing potential for whom a urine pregnancy test (with the test performed within the 24 hour period immediately prior to administration of 64Cu-LLP2A) is negative.\n\nInclusion Criteria Hematological Malignancy:\n\n* Clinical or pathologically defined MM or lymphoma including both newly diagnosed, relapsed or refractory disease:\n\n  * Multiple Myeloma defined in accordance with the International Myeloma Working Group criteria\n  * Low-grade lymphoma, including the following subtypes: follicular lymphoma, marginal zone lymphoma, lymphoplasmacytic lymphoma, small lymphocytic lymphoma\u002Fchronic lymphocytic leukemia\n* Adult 18 years of age or older and able to provide informed consent\n* Capable of lying still and supine within the PET\u002FCT scanner for up to 75 minutes.\n* No history of claustrophobia or other condition that has previously or would interfere with completion of protocol specified imaging sessions\n* Not currently pregnant or nursing: Subject must be surgically sterile (has had a documented bilateral oophorectomy and\u002For documented hysterectomy), post-menopausal (cessation of menses for more than 1 year), non-lactating, or of childbearing potential for whom a urine pregnancy test (with the test performed within the 24 hour period immediately prior to administration of 64Cu-LLP2A) is negative\n* Patients participating in imaging or therapeutic trials with investigational agents are eligible to participate",{"count":245,"type":21},42,[247],"EARLY_PHASE1","This phase of the protocol (protocol part B), seeks to evaluate the new formulation in healthy normal volunteers to confirm the new formulation provides comparable human dosimetry to which was seen and published in protocol part A. Additionally, the new formulation will be studied utilizing an expanded patient population to include patients with confirmed diagnosis of multiple myeloma (MM), low-grade lymphoma, or MM and lymphoma patients who are status post bone marrow transplant (BMT) with negative imaging and suspected recurrence.",[105,250,28,58,59,57,56],"Low-Grade Lymphoma",[252,253],"PET","Imaging","2026-06-15",{"date":178,"type":33},{"date":257,"type":33},"2025-03-20",{"date":259,"type":21},"2027-03-31",{"name":261,"class":73},"Washington University School of Medicine",{"id":263,"slug":264,"hasResults":12,"nctId":265,"briefTitle":266,"officialTitle":266,"acronym":4,"eligibilityCriteria":267,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":4,"targetDuration":4,"studyType":268,"phases":4,"briefSummary":269,"conditions":270,"keywords":4,"overallStatus":272,"whyStopped":4,"lastUpdateSubmitDate":273,"lastUpdatePostDateStruct":274,"startDateStruct":4,"completionDateStruct":4,"leadSponsor":276,"locationsCount":278},"100498892","expanded-access-study-for-the-treatment-of-patients-with-commercially-out-of-specification-axicabtagene-ciloleucel-100498892","NCT05776160","Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Axicabtagene Ciloleucel","Inclusion Criteria:\n\n* Have commercially manufactured axicabtagene ciloleucel that does not meet commercial release criteria but does meet Kite clinical trial release criteria\n* Females of childbearing potential must have a negative serum or urine pregnancy test (females who have undergone surgical sterilization or who have been post-menopausal for at least 2 years are not considered to be of childbearing potential)\n* Deemed medically fit and stable to receive the product per the investigator's evaluation\n* Repeat leukapheresis is not feasible per the investigator's assessment\n* Be diagnosed with 1 of the approved labeled indications for axicabtagene ciloleucel that is intended for release\n* In the investigator's opinion, there is no satisfactory alternative therapy available to the individual\n\nExclusion Criteria:\n\n* History of severe immediate hypersensitivity to any drugs or metabolites of similar chemical classes as axicabtagene ciloleucel\n* Uncontrolled active infection or inflammation per physician assessment\n* Primary central nervous system lymphoma","EXPANDED_ACCESS","The goal of this study is to provide access to axicabtagene ciloleucel for patients diagnosed with a disease approved for treatment with axicabtagene ciloleucel, that is otherwise out of specification for commercial release.",[271,28],"Large B-cell Lymphoma","AVAILABLE","2026-06-11",{"date":275,"type":33},"2026-06-12",{"name":277,"class":40},"Kite, A Gilead Company",128,{"id":280,"slug":281,"hasResults":12,"nctId":282,"briefTitle":283,"officialTitle":284,"acronym":285,"eligibilityCriteria":286,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":287,"targetDuration":4,"studyType":22,"phases":289,"briefSummary":290,"conditions":291,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":292,"lastUpdatePostDateStruct":293,"startDateStruct":295,"completionDateStruct":297,"leadSponsor":299,"locationsCount":301},"100635652","phase-2-mosunetuzumab-and-zeprumetostat-in-treating-patients-with-follicular-lymphoma-100635652","NCT07555470","Mosunetuzumab and Zeprumetostat in Treating Patients With Follicular Lymphoma","A Prospective, Multicenter, Phase 2 Study of Mosunetuzumab in Combination With Zeprumetostat for the Treatment of Follicular Lymphoma","CUREFL03","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2\n* Adequate hematologic and organ function\n* Female subjects of childbearing potential must have a negative serum pregnancy test and agree to use highly effective contraception; male subjects must agree to use effective contraception.\n* Voluntary written informed consent\n* Cohort 1- Previously Untreated High-Risk FL：\n\n  1. Histologically confirmed Grade 1-3a follicular lymphoma (FL), CD20-positive, with no evidence of histologic transformation\n  2. Ann Arbor Stage III\u002FIV\n  3. No prior systemic therapy for FL\n  4. Meeting at least one of the GELF criteria for indicating treatment\n  5. FLIPI-1 or FLIPI-2 score of 3 to 5 (High risk)\n* Cohort 2- Previously Untreated Low-Tumor-Burden FL：\n\n  1. Histologically confirmed Grade 1-3a, CD20-positive, Stage III\u002FIV FL with no prior systemic therapy.\n  2. Absence of B symptoms or severe pruritus\n  3. Low tumor burden (LTB) not meeting GELF criteria for treatment\n  4. Must have at least one measurable lesion (longest diameter \\>1.5 cm)\n  5. Patients who are suffering from the disease or prefer active management over a watch-and-wait approach\n* Cohort 3-Relapsed or Refractory FL：\n\n  1. Histologically confirmed Grade 1-3a, CD20-positive, Stage III\u002FIV FL with no evidence of histologic transformation.、\n  2. Relapsed or refractory disease, having received at least 1 prior systemic therapy regimen containing an anti-CD20 antibody\n  3. No prior treatment with a CD20\u002FCD3 bispecific antibody or an EZH2 inhibitor\n  4. Presence of at least one measurable or evaluable lesion at relapse\n\nExclusion Criteria:\n\n* Central nervous system (CNS) lymphoma, primary mediastinal lymphoma, or evidence of histologic transformation.\n* Uncontrolled cardiovascular, cerebrovascular, coagulopathy, connective tissue, or severe infectious diseases.\n* Pregnant or lactating women.\n* Known history of human immunodeficiency virus (HIV) or active hepatitis C virus (HCV) infection (RNA PCR positive).\n* Concurrent other malignancies or history of malignancies, or anti-cancer therapy (including major surgery) within the last 4 weeks.\n* Allergic reaction to the study drugs.\n* Concurrent use of strong CYP3A4 inhibitors or strong CYP3A4 inducers that cannot be avoided\n* Other medical or psychiatric conditions or laboratory abnormalities that, in the opinion of the investigator, may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results.",{"count":288,"type":21},80,[24],"The purpose of this prospective, multicenter, Phase 2 study is to evaluate the efficacy and safety of Mosunetuzumab in combination with the EZH2 inhibitor Zeprumetostat (SHR2554) in patients with follicular lymphoma (FL). The study plans to enroll approximately 80 patients, who will be assigned to three distinct cohorts: previously untreated high-risk FL (Cohort 1), previously untreated low-tumor-burden FL (Cohort 2), and relapsed or refractory FL (Cohort 3). The study consists of a safety run-in phase, which will be initially conducted in Cohort 1 to assess the tolerability of the combination therapy, followed by an expansion phase across all three cohorts to further evaluate the clinical outcomes.",[28],"2026-06-08",{"date":294,"type":33},"2026-06-09",{"date":296,"type":33},"2026-04-10",{"date":298,"type":21},"2029-12-31",{"name":300,"class":73},"Institute of Hematology & Blood Diseases Hospital, China",2,{"id":303,"slug":304,"hasResults":12,"nctId":305,"briefTitle":306,"officialTitle":307,"acronym":4,"eligibilityCriteria":308,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":309,"targetDuration":4,"studyType":311,"phases":4,"briefSummary":312,"conditions":313,"keywords":314,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":321,"lastUpdatePostDateStruct":322,"startDateStruct":324,"completionDateStruct":326,"leadSponsor":328,"locationsCount":74},"100300427","clonal-evolution-in-follicular-lymphoma-100300427","NCT03190928","Clonal Evolution in Follicular Lymphoma","Prospective Study of Clonal Evolution in Follicular Lymphoma","* INCLUSION CRITERIA:\n* Histologically or cytologically confirmed follicular lymphoma (FL), grades 1-2, or 3a confirmed by the Laboratory of Pathology, NCI; patients who meet criteria for immediate initiation of systemic therapy are eligible\n* Adequate tissue available from original diagnostic biopsy.\n\nNOTE: If biopsy was \\>12 months prior to enrollment OR adequate tissue is not available, tissue biopsy may be optionally repeated unless such a biopsy is considered unacceptable risk to the patient. Patients without adequate tissue are eligible at the discretion of the PI.\n\n\\- Must have disease that is measurable or evaluable on either computed tomography (CT) scans or FDG-positron emission tomography (FDG-PET) scans\n\nNOTE: Since patients with FL may have lesions that wax and wane on imaging, the requirement for disease being measurable or evaluable can come from imaging taken at any time at or after diagnosis, the most recent imaging prior to enrollment does not need\n\nto show measurable or evaluable disease.\n\n\\- Age greater than or equal to 18 years\n\nNOTE: Patients with the pediatric-type follicular lymphoma are usually \\\u003C18 years of age, and often have a very different clinical course than patients with the adult-type of FL. Due to this difference in biology, children are excluded from this study.\n\n\\- ECOG performance status \\\u003C2 (Karnofsky \\>60%)\n\nEXCLUSION CRITERIA:\n\n* Previous history of diffuse large B-cell lymphoma or histologic transformation\n* Any prior systemic treatment for lymphoma including cytotoxic chemotherapy, biologic therapy, and monoclonal antibody therapy (radiotherapy permitted); patients who have received chemotherapy, biologic therapy, hormonal therapy, or monoclonal antibody for other malignancies are potentially eligible provided that all of the following are true: a) that malignancy was not lymphoma, b) systemic therapy ended at least 3 years prior to the diagnosis of FL, and c) there is no evidence of active malignancy other than FL\n\nNOTE: Initiation of first-line systemic therapy is allowed while on this trial; concurrent participation in first-line treatment clinical trials will be permitted.\n\n* Patients who are HIV-positive\n* Any second malignancy that requires active systemic therapy\n* Any other (non-lymphoma) life-threatening disease\n* Patients unable to provide informed consent (surrogates will not be used)\n* Pregnant women are excluded from enrollment onto this study because the invasive procedures and\u002For sedation needed to perform them may cause unnecessary harm to the unborn fetus. In the event a woman becomes pregnant while on study, she will not be removed from the study; however, no follow-up invasive clinical or research procedures will be done that include unacceptable to risk to the patient and\u002For to the unborn fetus.",{"count":310,"type":21},200,"OBSERVATIONAL","Background:\n\nFollicular lymphoma is a type of cancer of the lymph nodes. Lab studies are important for cancer research. They help scientists better understand differences in the cancer biology of different patients. Researchers want to collect serial samples over time from people with follicular lymphoma to help them design future treatments.\n\nObjective:\n\nTo collect a variety of samples from people with follicular lymphoma to study how these diseases progress and respond to treatment.\n\nEligibility:\n\nAdults at least 18 years old who have been diagnosed with, but have not yet had any treatment for, follicular lymphoma.\n\nDesign:\n\nParticipants will be screened with medical history and physical exam. They will answer questions about daily functioning. They will have blood and urine tests. They may have scans and have tissue samples taken.\n\nParticipants will be monitored about every 4 months for up to 2 years. They will repeat screening tests. They will have a cheek swab. A small brush will be rubbed against the inside of the cheek to wipe off some cells.\n\nParticipants will have imaging scans about every 8 months for up to 2 years.\n\nParticipants may have a bone marrow aspiration and biopsy. The hipbone will be numbed with a small needle.\n\nA needle will be put into the hipbone, and about 2 tablespoons of bone marrow will be taken out through the needle.\n\nParticipants will continue being monitored every 6 months for up to 5 years, then 1 time a year.",[28],[315,316,317,318,319,320],"Disease Monitoring","Molecular Monitoring","Novel Biomarker Identification","Gene Expression Analyses","Watchful-Waiting","Natural History","2026-06-04",{"date":323,"type":33},"2026-06-05",{"date":325,"type":33},"2017-07-27",{"date":327,"type":21},"2029-01-01",{"name":329,"class":330},"National Cancer Institute (NCI)","NIH",{"id":332,"slug":333,"hasResults":12,"nctId":334,"briefTitle":335,"officialTitle":336,"acronym":337,"eligibilityCriteria":338,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":339,"targetDuration":4,"studyType":22,"phases":341,"briefSummary":342,"conditions":343,"keywords":346,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":321,"lastUpdatePostDateStruct":357,"startDateStruct":358,"completionDateStruct":360,"leadSponsor":361,"locationsCount":363},"100194258","phase-3-a-long-term-extension-study-of-pci-32765-ibrutinib-100194258","NCT01804686","A Long-term Extension Study of PCI-32765 (Ibrutinib)","A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study","CAN3001","Inclusion Criteria:\n\n* Participants must be currently participating in an ibrutinib clinical study considered complete and have received at least 6 months of treatment with ibrutinib. At study entry, participants must be actively receiving treatment with single-agent ibrutinib; or participants must have participated in an ibrutinib randomized clinical study in which they initially received comparator treatment and now cross-over to ibrutinib. Note: A minimum of 6 months requirement for prior ibrutinib treatment will not be mandatory in this case and participants with less than 6 months will be required to have more frequent initial safety assessments; or participants must be currently participating in study PCI-32765LYM1002. At study entry, participants must be actively receiving combination treatment with ibrutinib and nivolumab or single-agent ibrutinib\n* Investigator's assessment that the benefit of continued ibrutinib therapy as a single agent or in combination with nivolumab will outweigh the risks\n* Agrees to protocol-defined use of effective contraception\n* Negative blood or urine pregnancy test at screening\n\nExclusion Criteria:\n\n* Requires anticoagulation with warfarin or equivalent vitamin K antagonists\n* Requires treatment with strong cytochrome P450 (CYP)3A4\u002F5 inhibitors, unless previously approved by sponsor\n* Any condition or situation which, in the opinion of the investigator, may put the participant at significant risk, may confound the study results, or may interfere significantly with volunteer's participation in the study",{"count":340,"type":21},700,[25],"The purpose of this study is to collect long-term safety and efficacy data for participants treated with ibrutinib and to provide ongoing access to ibrutinib for participants who are currently enrolled in ibrutinib studies that have been completed according to the parent protocol, are actively receiving treatment with ibrutinib, and who continue to benefit from ibrutinib treatment.",[56,57,203,28,344,60,345],"Diffuse Large B-cell Lymphoma","Chronic Graft Versus Host Disease",[347,348,349,350,351,352,353,354,355,356],"Chronic lymphocytic leukemia","Small lymphocytic lymphoma","Mantle cell lymphoma","Follicular lymphoma","Diffuse large B-cell lymphoma","PCI-32765","Ibrutinib","Bruton's tyrosine kinase inhibitor","IMBRUVICA","JNJ-54179060",{"date":323,"type":33},{"date":359,"type":33},"2013-09-09",{"date":298,"type":21},{"name":362,"class":40},"Janssen Research & Development, LLC",175,{"id":365,"slug":366,"hasResults":12,"nctId":367,"briefTitle":368,"officialTitle":369,"acronym":370,"eligibilityCriteria":371,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":372,"targetDuration":4,"studyType":22,"phases":374,"briefSummary":375,"conditions":376,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":377,"lastUpdatePostDateStruct":378,"startDateStruct":379,"completionDateStruct":381,"leadSponsor":383,"locationsCount":385},"100537922","phase-3-study-of-mosunetuzumab-plus-lenalidomide-compared-to-anti-cd20-anti-body--chemotherapy-in-follicular-lymphoma-flipi2-5-100537922","NCT06284122","Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5","A Phase III Randomized, Open-label, International, Multicenter Study Evaluating the Efficacy and Safety of Mosunetuzumab Plus Lenalidomide in Comparison to Anti-CD20 Monoclonal Antibody Plus Chemotherapy in Subjects With Previously Untreated FLIPI 2-5 Follicular Lymphoma","MorningLyte","Inclusion Criteria:\n\n1. 1\\. Patient with histologically proven previously untreated CD20+ follicular lymphoma grade 1, 2, or 3a (including patient watched during up to 10 years after initial diagnosis) as assessed by the investigators according to the WHO 2016 classification12, or classical follicular lymphoma according to the WHO 2022 classification13. Diagnostic tissue must be available for central pathology review, exploratory endpoints and secondary data use.\n2. FLIPI 2-5.\n3. All Ann Arbor stages (including stage I if FLIPI ≥ 2).\n4. Must need treatment as evidenced by at least one of the following criteria:\n\n   4.1. Bulky disease defined as one of the following: 4.1.1. a nodal or extranodal mass\u002Flesion \\> 70 mm in its largest diameter or, 4.1.2. involvement of at least 3 different nodal or extranodal sites (each with a diameter greater than \\> 30 mm) 4.2. Presence of at least one of the following B symptoms within the prior 6 months: 4.2.1. fever (\\> 38°C) of unclear etiology 4.2.2. night sweats 4.2.3. weight loss greater than 10% 4.3. Symptomatic splenomegaly 4.4. Symptomatic lesion: 4.4.1. painful lesion and\u002For 4.4.2. any compressive syndrome (for example, but not restricted to- ureteral, orbital, gastrointestinal) 4.5. Any one of the following cytopenias due to lymphoma: 4.5.1. hemoglobin \\\u003C 10g\u002FdL (6.25 mmol\u002FL) 4.5.2. platelets \\\u003C100 x 109\u002FL, or 4.5.3. absolute neutrophil count (ANC) \\\u003C 1.5 x 109\u002FL 4.6. Pleural or peritoneal serous effusion (irrespective of cell content) 4.7. Abnormal biological prognostic parameters: (item not applicable for Germany) 4.7.1. β2microglobulin \\> ULN or 4.7.2. LDH \\> ULN\n5. At least one bi-dimensionally measurable nodal lesion, defined as \\> 15 mm in its longest dimension, or at least one bi-dimensionally measurable extra nodal lesion, defined as \\> 10 mm in its longest dimension (and FDG-avid lesion).\n6. Participant who understood and voluntarily signed and dated an informed consent prior to any study-specific assessments\u002Fprocedures.\n7. Must be ≥ 18 years old at the time of signing the informed consent form (ICF).\n8. ECOG performance status 0 to 2.\n9. Estimated minimum life expectancy of 3 months.\n10. Adequate hematological function within 28 days prior to randomization, including:\n\n    10.1. Absolute neutrophil count (ANC) ≥ 1 x 109\u002FL 10.2. Platelet count ≥ 75 x 109\u002FL, or ≥ 30 x 109\u002FL if bone marrow infiltration or splenomegaly 10.3. Hemoglobin ≥ 8.0 g\u002FdL (5 mmol\u002FL) unless related to bone marrow infiltration or splenomegaly. Transfusion is allowed before starting treatment (no required window)\n11. Normal laboratory values:\n\n    11.1. Measured or estimated creatinine clearance ≥ 40mL\u002Fmin calculated by institutional standard method (MDRD or Cockcroft-Gault 11.2. AST or ALT ≤ 2.5 x the upper limit of normal (ULN), except in patients with documented liver or pancreatic involvement by lymphoma ≤ 5 x ULN 11.3. Serum total bilirubin ≤ 1.5 x ULN (or ≤ 3 x ULN for patients with Gilbert syndrome), except in patients with documented liver or pancreatic involvement by lymphoma ≤ 3 x ULN\n12. LVEF within normal range (i.e. \\> 50% as evaluated by Transthoracic Echocardiography or \\> 45% as evaluated by isotopic method (MUGA scan).\n13. Participants should be able to receive adequate prophylaxis and\u002For therapy for thromboembolic events (aspirin, low molecular weight heparin or direct oral anticoagulants).\n\n    Patients with a curative anticoagulation therapy can be enrolled. A patient with deep vein thrombosis due to compressive syndrome is eligible if a curative anticoagulation therapy has been started at least 1 week before initiating study treatment: low molecular weight heparin possible at treatment onset, then direct oral anticoagulants according to local practices.\n14. Must be able to adhere to the study visit schedule and other protocol requirements.\n15. No more applicable following SM#14\n16. Negative HIV test before randomization, with the following exception:\n\n    Patients with a positive HIV test before randomization are eligible provided they are stable on antiretroviral therapy for at least 4 weeks, have a CD4 count ≥ 200\u002FuL, have an undetectable viral load, and have not had a history of opportunistic infection attributable to AIDS within the last 12 months.\n17. For women of childbearing potential (WOCBP) :\n\n    * must have a negative result for pregnancy test (highly sensitive serum) within 7 days before randomization and within 7 days before initiation of study treatment.\n    * must agree to abstain from becoming pregnant or breastfeeding, and agree to use highly effective contraceptive methods during study participation, and for at least 28 days after the final dose of lenalidomide (if applicable), 3 months after the final dose of mosunetuzumab and tocilizumab (if applicable), 12 months after the final dose of CHOP (if applicable), 6 months after the final dose of bendamustine (if applicable), 12 months after the final dose of rituximab (if applicable), and 18 months after the final dose of obinutuzumab (if applicable).\n18. For men with a female partner of childbearing potential or pregnant female partner, men must remain abstinent or use a condom during the treatment period (including periods of treatment interruption), and for at least 07 days after the final dose of lenalidomide (if applicable), 2 months after the final dose of tocilizumab (if applicable), 6 months after the final dose of CHOP (if applicable), 3 months after the final dose of bendamustine (if applicable), 12 months after the final dose of rituximab (if applicable), and 3 months after the final dose of obinutuzumab (if applicable). Men must also agree to refrain from donating sperm from the first day of treatment until at least 7 days after the final dose of lenalidomide (if applicable), 2 months after the final dose of tocilizumab (if applicable), 6 months after the final dose of CHOP (if applicable), 3 months after the final dose of bendamustine (if applicable), 12 months after the final dose of rituximab (if applicable), and 3 months after the last dose of obinutuzumab (if applicable).\n19. Participant covered by any social security system (France).\n20. Participant who understands and speaks one of the country official languages, unless local regulation authorizes independent translators.\n\nExclusion criteria:\n\n1. Grade 3b follicular lymphoma according to the WHO 2016 classification12, or follicular large B-cell lymphoma according to the WHO 2022 classification13\n2. Suspicion or clinical evidence of transformed lymphoma at enrollment by investigator assessment.\n\n   Examples: patients with high or intermediate high SUV (\\>20) in any nodal or extranodal site particularly in the bones (vertebrae etc) unless biopsy proven to be genuine FL grade 1,2, 3A ; and\u002For discordant (e.g. SUV doubled) with SUV of other sites including the biopsy site.; and\u002For LDH \\> 2.5 x ULN in a context of rapidly progressive disease, etc. Please contact the Coordinating Investigator \u002F Sponsor to discuss such cases or if there is any doubt before considering enrolment.\n3. Prior localized radiotherapy for the FL.\n4. Prior history of another lymphoma.\n5. Uncontrolled symptomatic pleural or serous effusion requiring urgent treatment (within one week of finding). Participants may only be enrolled after Coordinating investigator \u002F sponsor approval once confirmed participant is durably asymptomatic after adequate pleural\u002Fserous drainage or only if an efficient drainage device (e.g.pleurX™) is in place before randomization.\n6. Uncontrolled symptomatic ureterohydronephrosis resulting in renal failure. Participants with adequate management i.e. ureteral catheter or double J stent allowing renal failure control are eligible only if urinary catheter is in place before randomization.\n7. Presence or history of symptomatic or threatening lymphomatous epidural\u002Fnerve root lesion, even such participants whose disease is controlled by short course of steroids are NOT eligible.\n8. Use of any standard or experimental anti-cancer drug therapy within 45 days of the start (Day 1) of study treatment.\n9. Any contraindication to any drug contained in the study treatment control arms or in the Auxiliary Medicinal Products (AxMPs)\n10. Systemic immunosuppressive medications (including, but not limited to, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor agents) and corticosteroids on the long run with the following exceptions: inhaled steroids for asthma, topical steroids, or replacement or stress corticosteroids during the study at any time. Participants who require lymphoma symptom control during screening may receive corticosteroid \\\u003C or = 1mg\u002Fkg\u002Fday prednisone or equivalent for a maximum of 10 days prior to first dose of study treatment\n11. Received a live, attenuated vaccine within 4 weeks before the first dose of study treatment, or in whom it is anticipated that such a live attenuated vaccine will be required during the study period or within 6 months after the final dose of study treatment.\n12. Major surgery (excluding surgical documentation of FL) within 28 days prior to signing informed consent.\n13. Seropositive for or active viral infection with hepatitis B virus (HBV):\n\n    * HBsAg positive\n    * HBsAg negative, anti-HBs positive and\u002For anti-HBc positive and detectable viral DNA (Patients who are HBsAg negative, anti-HBs positive and\u002For anti-HBc positive but viral DNA negative are eligible. They should be treated and perform testing at regular interval described in section Anti infectious prophylaxis; Patients who are seropositive due to a history of hepatitis B vaccine (anti-HBs positive) are eligible).\n14. Known seropositive for, or active infection hepatitis C virus (HCV) (Patients who are positive for HCV antibody with a negative viral RNA are eligible).\n15. Known or suspected hypersensitivity to biopharmaceuticals produced in CHO cells or any component of the mosunetuzumab, anti-CD20 mAb, tocilizumab, lenalidomide formulation, including mannitol; or to any of the excipients.\n16. History of solid organ transplantation or allogeneic stem cell transplant (SCT).\n17. Active autoimmune disease requiring treatment.\n18. History of autoimmune disease, including, but not limited to, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener granulomatosis, Sjögren syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, uveitis, or glomerulonephritis.\n\n    * Participants with a history of autoimmune-related hypothyroidism on a stable dose of thyroid replacement hormone may be eligible.\n    * Participants with controlled Type 1 diabetes mellitus who are on an insulin regimen are eligible for the study.\n    * Participants with a remote history of, or well-controlled autoimmune disease, with a treatment-free interval from immunosuppressive therapy for 12 months may be eligible after review and discussion with the Coordinating investigator.\n19. Participants with any active infection such as known active bacterial, viral (including SARS-CoV-2), fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds), known or suspected chronic active Epstein-Barr virus (EBV) infection are excluded.\n20. Evidence of any significant, concomitant disease that could affect compliance with the protocol or interpretation of results, including, but not limited to:\n\n    * significant cardiovascular disease \\[e.g., Objective Class C or D heart diseases (cf. Classes of Heart Failure \\| American Heart Association), myocardial infarction within the previous 6 months, unstable arrhythmia, or unstable angina)\n    * significant pulmonary disease (such as obstructive pulmonary disease or history of bronchospasm)\n    * clinically significant history of liver disease, including viral or other hepatitis, or cirrhosis\n    * current or past history of central nervous system (CNS) disease, such as stroke, epilepsy, CNS vasculitis, or neurodegenerative disease. Participants with a history of stroke who have not experienced a stroke or transient ischemic attack in the past 1 year and have no residual neurologic deficits as judged by the investigator are allowed. Participants with a history of epilepsy who have had no seizures in the past 2 years with or without anti-epileptic medications can be eligible.\n21. History of confirmed progressive multifocal leukoencephalopathy (PML).\n22. Known or suspected history of hemophagocytic lymphohistiocytosis (HLH).\n23. History of erythema multiforme, Grade ≥3 rash, or blistering rash following prior treatment with immunomodulatory derivatives.\n24. History of interstitial lung disease (ILD), drug-induced pneumonitis, and autoimmune pneumonitis.\n25. Active malignancy other than the one treated in this research. Prior history of malignancies unless the patient has been free of the disease and therapy for ≥ 3 years. However, patients with a single occurrence of the following conditions that have been treated with curative intent are eligible:\n\n    * Localized non-melanoma skin cancer.\n    * Carcinoma in situ of the cervix.\n    * Carcinoma in situ of the breast.\n    * Incidental histologic finding of prostate cancer (T1a or T1b as per Tumor Node Metastasis \\[TNM\\] staging system) or prostate cancer.\n26. Presence or history of CNS or meningeal involvement by lymphoma.\n27. Pregnant, planning to become pregnant or lactating WOCBP.\n28. Any significant medical conditions, including the presence of laboratory abnormality or psychiatric illness which places the patient at unacceptable risk if he\u002Fshe were to participate in the study, and likely to interfere with participation in this clinical study (according to the investigator's decision) or which confounds the ability to interpret data from the study.\n29. Person deprived of his\u002Fher liberty by a judicial or administrative decision.\n30. Person hospitalized without consent.\n31. Adult person under legal protection.\n32. Patients with absolute lymphocyte count \\> 20 G\u002FL before randomization. Participants circulating lymphoma cell≥ 5 G\u002FL must be discussed with the Sponsor before randomization.\n\nNB: for 29-31., if there is an individual benefit for such patients, an Ethics Committee will have to be informed case by case.",{"count":373,"type":21},790,[25],"This study is a phase III, randomized, open-label, international, multicenter, interventional trial, designed to compare the efficacy and safety of mosunetuzumab in combination with lenalidomide versus anti-CD20 monoclonal antibody (mAb) plus chemotherapy in patients with previously untreated FLIPI 2-5 follicular lymphoma.",[28],"2026-06-03",{"date":323,"type":33},{"date":380,"type":33},"2024-06-07",{"date":382,"type":21},"2034-04",{"name":384,"class":73},"The Lymphoma Academic Research Organisation",116,{"id":387,"slug":388,"hasResults":12,"nctId":389,"briefTitle":390,"officialTitle":391,"acronym":4,"eligibilityCriteria":392,"healthyVolunteers":12,"sex":17,"minAge":393,"maxAge":394,"enrollmentInfo":395,"targetDuration":4,"studyType":311,"phases":4,"briefSummary":397,"conditions":398,"keywords":410,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":414,"lastUpdatePostDateStruct":415,"startDateStruct":416,"completionDateStruct":418,"leadSponsor":420,"locationsCount":422},"100526212","pharmacokinetic-study-of-venetoclax-tablets-crushed-and-dissolved-into-a-solution-100526212","NCT06131801","Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution","A Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution in Children and Young Adults With Hematologic Malignancies","Inclusion Criteria:\n\n* Age: Patients must be \\\u003C39 years of age at time of study enrollment\n* Diagnosis: Patients may have a diagnosis of any hematologic malignancy\n* Central access: Patients must have an existing venous or arterial access line for PK blood draws\n* Weight requirement: Patients must weigh at least 5.5 kg at the time of enrollment\n* Venetoclax: Patients must be receiving any dose of venetoclax given as a solution made from crushed tablets by mouth (PO) or via nasogastric (NG), or G-tube as prescribed by their treating oncologist.\n* Concurrent chemotherapy medications: Patients may receive venetoclax as a single agent or in combination with any other chemotherapeutic agents.\n\nExclusion Criteria:\n\n* Pregnant women are excluded from this study because venetoclax has the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with venetoclax, breastfeeding should be discontinued if the mother is treated with venetoclax.\n* Males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method while on study treatment and for six months following completion.","0 Years","38 Years",{"count":396,"type":21},30,"The use of venetoclax-based therapies for pediatric patients with relapsed or refractory malignancies is increasingly common outside of the clinical trial setting. For patients who cannot swallow tablets, it is common to crush the tablets and dissolve them in liquid to create a solution. However, no PK data exists in adults or children using crushed tablets dissolved in liquid in this manner, and as a result, the venetoclax exposure with this solution is unknown.\n\nPrimary Objectives\n\n• To determine the pharmacokinetics of venetoclax when commercially available tablets are crushed and dissolved into a solution\n\nSecondary Objectives\n\n* To evaluate the safety of crushed venetoclax tablets administered as an oral solution\n* To determine the pharmacokinetics of venetoclax solution in patients receiving concomitant strong and moderate CYP3A inhibitors\n* To determine potential pharmacokinetic differences based on route of venetoclax solution administration (ie. PO vs NG tube vs G-tube)\n* To determine the concentration of venetoclax in cerebral spinal fluid when administered as an oral solution",[399,400,55,401,17,402,112,91,116,403,404,405,204,28,103,406,407,408,409],"Hematologic Malignancy","Leukemia","Acute Lymphocytic Leukemia","Acute Myelogenous Leukemia","Myeloproliferative Neoplasm","Non Hodgkin Lymphoma","Hodgkin Lymphoma","T-cell Lymphoma","B Cell Lymphoma","Peripheral T Cell Lymphoma","Cutaneous B-Cell Lymphoma",[411,412,413],"Venetoclax","Pediatric AML","Pediatric Relapsed\u002FRefractory AML","2026-06-02",{"date":321,"type":33},{"date":417,"type":33},"2023-11-15",{"date":419,"type":21},"2027-12-01",{"name":421,"class":73},"Children's Hospital Medical Center, Cincinnati",5,{"id":424,"slug":425,"hasResults":12,"nctId":426,"briefTitle":427,"officialTitle":428,"acronym":429,"eligibilityCriteria":430,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":431,"targetDuration":4,"studyType":22,"phases":433,"briefSummary":434,"conditions":435,"keywords":436,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":446,"lastUpdatePostDateStruct":447,"startDateStruct":449,"completionDateStruct":451,"leadSponsor":453,"locationsCount":455},"100510652","phase-3-comparison-between-local-radiotherapy-alone-or-combined-with-obinutuzumab-in-early-stage-follicular-lymphoma-the-gazebo-trial-from-the-fondazione-italiana-linfomi-100510652","NCT05929222","Comparison Between Local Radiotherapy Alone or Combined With Obinutuzumab in Early Stage Follicular Lymphoma: the GAZEBO Trial From the Fondazione Italiana Linfomi","An Open-label, Randomized Phase III Trial Comparing Local Radiotherapy Alone or Combined With Obinutuzumab in Early Stage Follicular Lymphoma: the GAZEBO Trial From the Fondazione Italiana Linfomi","FIL_GAZEBO","Inclusion Criteria:\n\n1. Histological documented diagnosis of Follicular Lymphoma grade I-IIIA as defined in the 2017 edition of World Health Organization (WHO)\n2. Ann Arbor Stage IA or IIA (includible in one radiation field), or IE, non-bulky (\\\u003C7 cm). Stage must be determined by PET\u002FCT scan (Appendix 2)\n3. Patients performing PET before surgery can also be enrolled without repeating PET after surgery\n4. No previous treatment except for steroid pre-treatment\n5. FLIPI \\\u003C 2, FLIPI2 ≤ 2\n6. Age ≥ 18 years\n7. Negative bone marrow biopsy\n8. Qualitative\u002Fquantitative PCR centralized assessment of BCL2\u002FIGH positive cells in peripheral blood (PB), bone marrow (BM).\n9. Centralized revision of the lymph node biopsy with FISH for t(14;18)\n10. Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 2\n11. At least one site of measurable nodal disease pre-biopsy ≥ 2.0 cm in the longest transverse diameter as determined by CT scan or ultrasonography\n12. Adequate renal function defined as follows:\n\n    * Creatinine clearance ≥ 40 mL\u002Fmin (Cockcroft-Gault formula)\n13. Adequate hepatic function per local laboratory reference range as follows:\n\n    * Aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 3.0 x UNL\n    * Bilirubin ≤1.5 x UNL (unless bilirubin rise is due to Gilbert's syndrome or of non-hepatic origin)\n14. Subject understands and voluntarily signs an informed consent form approved by an Independent National Ethics Committee (NEC), prior to the initiation of any screening or study-specific procedures\n15. Subject must be able to adhere to the study visit schedule and other protocol requirements\n16. Life expectancy ≥ 3 months\n17. Fertility and pregnancy prevention criteria\n\n    * Women must be:\n\n      * postmenopausal for at least 1 year (must not have had a natural menses for at least 12 months)\n      * surgically sterile (have had a hysterectomy or bilateral oophorectomy, tubal ligation, or otherwise be incapable of pregnancy),\n      * completely abstinent (periodic abstinence from intercourse is not permitted) or if sexually active, be practicing a highly effective method of birth control (e.g., prescription oral contraceptives, contraceptive injections, contraceptive patch, intrauterine device, double barrier method (e.g.: condoms, diaphragm, or cervical cap, with spermicidal foam, cream, or gel, male partner sterilization) as local regulations permit, before entry, and must agree to continue to use the same method of contraception throughout the study. They must also be pre-pared to continue birth control measures for at least 18 months after terminating treatment.\n    * Women of childbearing potential must have a negative pregnancy test at screening\n    * Men with female partners of childbearing potential: men must remain abstinent or use a condom plus an additional contraceptive method that together result in a failure rate of \\\u003C 1% per year during the treatment period and for at least 3 months after the last dose of study treatment. Men must refrain from donating sperm for the same period\n    * Male even if surgically sterilized (i.e., status post vasectomy) must agree to 1 of the following\n\n      * practice effective barrier contraception during the entire study treatment period and through 3 months after the last dose of study drug, or\n      * agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence \\[e.g., calendar, ovulation, symptothermal, post ovulation methods for the female partner\\] and withdrawal are not acceptable methods of contraception)\n\nExclusion Criteria:\n\n1. Histological diagnosis of Follicular lymphoma grade IIIb\n2. Staging \\>II or B symptoms or bulky disease (\\> 7 cm)\n3. Stage II with distant involved sites, not includible in a single radiation field\n4. Primary cutaneous follicular lymphoma\n5. Known HIV positivity\n6. Positive serology for hepatitis C (HC) defined as a positive test for HCAb, in which case reflexively perform a HC RNA on the same sample to confirm the result, if negative, the patient is eligible.\n7. Positive serology for Hepatitis B (HB) defined as a positive test for HBsAg. In addition, if negative for HBsAg but HBcAb positive (regardless of HBsAb status), a quantitative HBVDNA test will be performed and if positive the subject will be excluded. Patients with HBcAb positivity and negative HBV DNA should be prophylactically treated with oral Lamivudine (100 mg \u002Fday). Note: subjects with serologic evidence of prior vaccination to HBV (i.e., hepatitis B surface (HBs) antigen negative, anti-HBs antibody positive and anti-hepatitis B core (HBc) antibody negative) or positive anti-HBc antibody from intravenous immunoglobulins (IVIG) may participate\n8. Central Nervous System (CNS) involvement with lymphoma\n9. Significant history of neurologic, psychiatric, endocrinological, metabolic, immunologic, or hepatic disease that would preclude participation in the study or compromise ability to give informed consent\n10. Any history of other active malignancies within 3 years prior to study entry, except for adequately treated in situ carcinoma of the cervix uterine, basal cell carcinoma of the skin or localized squamous cell carcinoma of the skin, previous malignancy confined and surgically resected with curative intent\n11. Evidence of other clinically significant uncontrolled condition(s) including, but not limited to:\n\n    * Uncontrolled and\u002For active systemic infection (viral, bacterial or fungal)\n    * Chronic hepatitis B virus (HBV) or hepatitis C (HCV) requiring treatment.\n12. If female, the patient is pregnant or breast-feeding\n13. Patients participating in other clinical studies.",{"count":432,"type":21},190,[25],"Prospective, multicenter, open label, phase III randomized clinical trial in previously untreated Follicular Lymphoma in early stage. Patients will be randomized to receive Radiotherapy or Radiotherapy plus Obinutuzumab.",[28],[55,437,438,439,440,441,442,443,444,445,252],"Follicular","Immunotherapy","FL","Radiotherapy","Early","Localized","Obinutuzumab","MRD","Minimal residual disease","2026-05-29",{"date":448,"type":33},"2026-06-01",{"date":450,"type":33},"2023-12-14",{"date":452,"type":21},"2031-04",{"name":454,"class":73},"Fondazione Italiana Linfomi - ETS",49,{"id":457,"slug":458,"hasResults":12,"nctId":459,"briefTitle":460,"officialTitle":461,"acronym":4,"eligibilityCriteria":462,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":463,"targetDuration":464,"studyType":311,"phases":4,"briefSummary":465,"conditions":466,"keywords":4,"overallStatus":469,"whyStopped":4,"lastUpdateSubmitDate":470,"lastUpdatePostDateStruct":471,"startDateStruct":473,"completionDateStruct":475,"leadSponsor":477,"locationsCount":74},"100638914","pomalidomide-plus-anti-cd20-antibody-and-prednisone-in-frontline-indolent-b-cell-lymphoma-100638914","NCT07609446","Pomalidomide Plus Anti-CD20 Antibody and Prednisone in Frontline Indolent B-Cell Lymphoma","Pomalidomide Plus Anti-CD20 Antibody and Prednisone in Frontline Indolent B-Cell Lymphoma: A Prospective, Multicenter, Phase II Study","Inclusion Criteria:\n\n1. Age ≥ 18 years, regardless of sex;\n2. Confirmed diagnosis of follicular lymphoma (FL), or histopathologically confirmed CD20-positive marginal zone lymphoma (MZL), including extranodal marginal zone lymphoma (MALT), splenic marginal zone lymphoma (SMZL), and nodal marginal zone lymphoma (NMZL),or confirmed diagnosis of indolent mantle cell lymphoma (MCL);\n3. Patients with a confirmed diagnosis of chronic lymphocytic leukemia (CLL)\u002Fsmall lymphocytic lymphoma (SLL);\n4. Confirmed diagnosis of lymphoplasmacytic lymphoma\u002FWaldenstrom macroglobulinemia;\n5. Presence of indications for treatment of indolent B-cell lymphoma;\n6. No prior systemic antitumor therapy for lymphoma;\n7. ECOG-PS score 0-2;\n8. Essentially normal bone marrow hematopoietic function, with routine blood tests as follows: white blood cell count \\>3000\u002FuL, absolute neutrophil count ≥1.5 × 10\\^9\u002FL (use of granulocyte colony-stimulating factor is allowed), platelet count ≥75 × 10\\^9\u002FL (transfusion to reach this minimum platelet count is allowed), and hemoglobin ≥9.0 g\u002FdL (prior red blood cell transfusion or use of recombinant human erythropoietin is allowed). If peripheral blood abnormalities are caused by lymphoma involvement of the bone marrow or spleen, neutrophils≥1.0 × 10\\^9\u002FL and platelets≥50 × 10\\^9\u002FL are acceptable (the investigator may determine at his\u002Fher discretion whether enrollment is appropriate);\n9. Normal function of major organs:\n\n   1. Hepatic function: serum bilirubin ≤2.0 × ULN; serum ALT and AST ≤2.5 × ULN;\n   2. Renal function: creatinine clearance \\>30 mL\u002Fmin;\n10. Expected survival≥3 months as judged by the investigator; Voluntary written informed consent signed before trial screening;\n\nExclusion Criteria:\n\n1. Current or prior other malignancy, unless curative treatment has been performed and there has been no evidence of recurrence or metastasis within the past 5 years;\n2. Lymphoma involvement of the central nervous system or transformation to a higher-grade lymphoma;\n3. Hepatic or renal dysfunction unrelated to lymphoma: alanine aminotransferase (ALT) \\>3 times the upper limit of normal, aspartate aminotransferase (AST) \\>3 times the upper limit of normal, total bilirubin (TBIL) \\>2 times the upper limit of normal, or serum creatinine \\>1.5 times the upper limit of normal;\n4. Other serious medical conditions that would affect this study (e.g., uncontrolled diabetes, gastric ulcer, or other serious cardiopulmonary diseases). The investigator has the authority to make this determination;\n5. Severe or uncontrolled infection;\n6. Clinically manifest central nervous system dysfunction;\n7. Major surgery within the past 30 days (excluding lymph node biopsy);\n8. Pregnant or lactating women, or women of childbearing potential who have not used contraceptive measures;\n9. Allergy to the study drug; Patients considered unsuitable for enrollment by the investigator.",{"count":396,"type":21},"12 Months","A Phase II Study of Pomalidomide Combined with Anti-CD20 Monoclonal Antibody and Prednisone in Frontline Indolent B-Cell Lymphoma Objective: This prospective, single-arm, Phase II trial aims to evaluate the efficacy and safety of first-line pomalidomide plus anti-CD20 antibody and prednisone in patients with indolent B-cell lymphoma.\n\nStudy Population: Approximately 30 adult patients (age ≥18 years) will be enrolled. Eligible histologies include follicular lymphoma (FL), CD20-positive marginal zone lymphoma (MZL: extranodal MALT, splenic SMZL, nodal NMZL), indolent mantle cell lymphoma (MCL), chronic lymphocytic leukemia\u002Fsmall lymphocytic lymphoma (CLL\u002FSLL), and lymphoplasmacytic lymphoma\u002FWaldenström macroglobulinemia. Patients must be treatment-naïve, have an indication for systemic therapy, ECOG performance status 0-2, and adequate bone marrow reserve (ANC ≥1.5×10⁹\u002FL, platelets ≥75×10⁹\u002FL, hemoglobin ≥9.0 g\u002FdL; lower thresholds permitted if marrow\u002Fspleen involvement, per investigator discretion). Adequate organ function is required: bilirubin ≤2×ULN, ALT\u002FAST ≤2.5×ULN, and creatinine clearance \\>30 mL\u002Fmin. Life expectancy must be ≥3 months, and written informed consent is mandatory.\n\nExclusion Criteria: Patients are excluded if they have another malignancy within 5 years (unless curatively treated without recurrence), CNS lymphoma involvement, transformation to high-grade lymphoma, uncontrolled infection, severe comorbidities affecting study participation, significant non-lymphoma-related organ dysfunction (ALT\u002FAST \\>3×ULN, bilirubin \\>2×ULN, creatinine \\>1.5×ULN), active CNS dysfunction, major surgery within 30 days, pregnancy or lactation, lack of contraception in women of childbearing potential, known drug hypersensitivity, or any condition deemed unsuitable by the investigator.\n\nTreatment Regimen: Induction consists of six 28-day cycles. Anti-CD20 antibody is administered at 375 mg\u002Fm² weekly during Cycle 1 and on Day 1 of Cycles 2-6. Pomalidomide is given at 4 mg\u002Fday on Days 2-22 of Cycles 1-6. Prednisone is administered at 100 mg\u002Fday on Days 1-5 of Cycles 1-6. Maintenance therapy continues for 2 years with pomalidomide 4 mg\u002Fday on Days 1-14 and anti-CD20 antibody 375 mg\u002Fm² on Day 1 every 8 weeks.\n\nEndpoints: The primary endpoint is overall response rate (ORR). Secondary endpoints include complete response rate (CR), progression-free survival (PFS), overall survival (OS), and safety (hematologic and non-hematologic adverse events).\n\nStatistical Methods: Continuous variables will be summarized with descriptive statistics; categorical variables with frequencies and percentages. Time-to-event endpoints (PFS, OS, and duration of response) will be analyzed using the Kaplan-Meier method, reporting medians, quartiles, and 90% confidence intervals, along with event and censoring counts. ORR will be tested statistically and reported with a 90% confidence interval.\n\nTimeline: The study is expected to begin in January 2026, complete enrollment by December 2026, and conclude by December 2027. The total planned sample size is 30 patients.",[467,28,58,468],"Indolent Lymphoma","Indolent Mantle Cell Lymphoma","NOT_YET_RECRUITING","2026-05-21",{"date":472,"type":33},"2026-05-27",{"date":474,"type":21},"2026-05-01",{"date":476,"type":21},"2027-12-31",{"name":478,"class":73},"The First Affiliated Hospital of Soochow University",{"id":480,"slug":481,"hasResults":12,"nctId":482,"briefTitle":483,"officialTitle":484,"acronym":4,"eligibilityCriteria":485,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":486,"targetDuration":4,"studyType":22,"phases":488,"briefSummary":489,"conditions":490,"keywords":492,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":494,"lastUpdatePostDateStruct":495,"startDateStruct":497,"completionDateStruct":499,"leadSponsor":500,"locationsCount":502},"100499465","phase-2-epcoritamab-and-rituximab-for-first-line-follicular-lymphoma-100499465","NCT05783609","Epcoritamab and Rituximab for First-line Follicular Lymphoma","A Phase 2 Study of Epcoritamab and Rituximab for First-line Treatment of Follicular Lymphoma","Inclusion Criteria:\n\n* Histologically confirmed diagnosis of CD20+ FL (grade 1-3A) with review of the diagnostic pathology specimen at one of the participating institutions. Patients with current or prior histologic transformation are excluded.\n* No prior systemic therapy for FL. Prior treatment with radiation therapy or short course steroids is allowed.\n* Meets at least one criterion to begin treatment based on the modified GELF (Groupe d'Etude des Lymphomes Folliculaires) criteria:\n\n  * Symptomatic adenopathy\n  * Organ function impairment due to disease involvement, including cytopenias due to marrow involvement (WBC \\\u003C1.5x109\u002FL; absolute neutrophil count \\[ANC\\] \\\u003C1.0x109\u002FL, Hgb \\\u003C10g\u002FdL; or platelets \\\u003C100x109\u002FL)\n  * Constitutional symptoms (defined as persistent fevers \\>100.4 F, shaking chills, drenching night sweats, or loss of \\>10% of body weight within a 6 month period)\n  * Any nodal or extranodal tumor mass \\>7 cm in maximum diameter\n  * \\>3 nodal sites of involvement \\>3 cm\n  * Local compressive symptoms or imminent risk thereof\n  * Splenomegaly (craniocaudal diameter \\> 16cm on CT imaging)\n  * Clinically significant pleural or peritoneal effusion\n  * Leukemic phase (\\>5x109\u002FL circulating malignant cells)\n  * Rapid generalized disease progression\n  * Renal infiltration\n  * Bone lesions\n* Patients cannot be in need of urgent cytoreductive chemotherapy (in the opinion of the treating investigator).\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. (Appendix A)\n* Age ≥18 years.\n* Adequate hematologic and organ function:\n\n  1. Absolute neutrophil count \\> 1.0x109\u002FL unless due to marrow involvement by lymphoma in which case ANC must be \\>0.5x109\u002FL\n  2. Platelets \\> 75 x109\u002FL, unless due to marrow involvement by lymphoma, in which case platelets must be \\>50 x109\u002FL\n  3. Estimated CrCl (Cockcroft Gault) ≥ 45ml\u002Fmin\n  4. Total bilirubin \\\u003C 1.5 X ULN, unless Gilbert syndrome, in which case direct bilirubin must be \\\u003C 1.5 x ULN\n  5. AST\u002FALT \\\u003C 2.5 X ULN, unless documented liver involvement by lymphoma, in which case AST\u002FALT must be \\\u003C5 x ULN\n* Ability to understand and the willingness to sign a written informed consent document.\n* Willingness to provide a pre-treatment tumor sample by core needle or excisional surgical biopsy. A fresh biopsy is strongly encouraged, but an archival sample is acceptable if the following provisions are met: 1) availability of a tumor-containing formalin-fixed, paraffin-embedded (FFPE) tissue block, 2) if the tumor containing FFPE tissue block cannot be provided in total, sections from this block should be provided that are freshly cut and mounted on positively-charged glass slides. Preferably, 25 slides should be provided; if not possible, a minimum of 15 slides is required. Exceptions to this criterion may be made with approval of the Sponsor-Investigator.\n* Willingness to remain abstinent or to use two effective contraceptive methods that result in a failure rate of \\\u003C1% per year from screening until: (a) at least 3 months after pre-treatment with rituximab or 12 months after the last dose of epcoritamab, whichever is longer, if the patient is a male or (b) until at least 18 months after pre-treatment with rituximab or 12 months after the last dose of epcoritamab, whichever is longer, if patient is a female. Examples of contraceptive methods with a failure rate of \\\u003C1% per year include:\n\n  * Tubal ligation, male sterilization, hormonal implants, established proper use of hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices.\n  * Alternatively, two methods (e.g., two barrier methods such as a condom and a cervical cap) may be combined to achieve a failure rate of \\\u003C1% per year. Barrier methods must always be supplemented with the use of a spermicide.\n\nExclusion Criteria:\n\n* Patients who require systemic immunosuppressive therapy for an ongoing medical condition will be excluded. For corticosteroids, patients receiving a prednisone dose of \\>10 mg daily (or equivalent) will not be eligible. A short course of steroids (up to 14 days) for symptom palliation is allowed, in which case patients should be off steroids prior to treatment start.\n* Patients with bulky cervical adenopathy that is compressing the upper airway or could result in significant airway compression during a tumor flare event.\n* Patients with stage I follicular lymphoma\n* Patients who are candidates for radiation therapy with curative intent (in the opinion of the treating investigator)\n* Patients, who have had a major surgery or significant traumatic injury within 4 weeks of start of study drug, patients who have not recovered from the side effects of any major surgery (defined as requiring general anesthesia).\n* Active HBV (DNA PCR-positive) or hepatitis C (RNA PCR-positive infection). Subjects with evidence of prior HBV but who are PCR-negative are permitted in the trial but should receive prophylactic antiviral therapy. Subjects who received treatment for HCV that was intended to eradicate the virus may participate if hepatitis C RNA levels are undetectable.\n* Known history of seropositivity for human immunodeficiency virus (HIV). Note: HIV testing is required at screening only if required per local health authorities or institutional standards.\n* Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at trial enrolment or significant infections within 2 weeks prior to the first dose of epcoritamab.\n* Prior history of another malignancy (except for non-melanoma skin cancer or in situ cervical or breast cancer) unless disease free for at least 2 years.\n* Patients should not have received immunization with attenuated live vaccine within one week of study entry or during study period.\n* Patients who have any severe and\u002For uncontrolled medical conditions or other conditions that could affect their participation in the study or limit adherence to study requirements.\n* Patients with any one of the following currently on or in the previous 6 months will be excluded: myocardial infarction, congenital long QT syndrome, torsade de pointes, unstable angina, coronary\u002Fperipheral artery bypass graft, cardiac arrhythmia (CTCAE grade 3 or higher), clinically significant ECG abnormalities, or cerebrovascular accident.\n* Patients with New York Heart Association Class III or IV heart failure or known ejection fraction of \\\u003C45%.\n* Inability to comply with protocol mandated hospitalizations and restrictions.\n* Patients who are pregnant, breast-feeding, or intending to become pregnant during the study.\n* Prior solid organ or allogeneic stem cell transplantation.\n* History of known or suspected hemophagocytic lymphohistiocytosis (HLH).\n* History of autoimmune disease, including but not limited to myocarditis, pneumonitis, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis.\n\n  • Patients with a remote history of, or well controlled, autoimmune disease who meet above criteria may be eligible to enroll after consultation with the Sponsor-Investigator.\n* History of severe allergic or anaphylactic reactions to anti-CD20 mAb therapy or known allergy or intolerance to any component or excipient of epcoritamab.\n* Vaccination with live vaccines within 28 days prior to the first dose of epcoritamab.\n* Active CNS lymphoma\n* Neuropathy \\> grade 2. (CTCAE)\n* Treatment with CAR-T therapy within 100 days prior to first dose of epcoritamab.\n* Treatment with an investigational drug within 4 weeks or 5 half-lives, whichever is longer, prior to the first dose of epcoritamab.\n* Chemotherapy and other non-investigational anti-neoplastic agents (except CD20 mAbs) within 4 weeks or 5 half-lives (whichever is shorter) prior to the first dose of epcoritamab.\n* No known active severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. If a subject has signs\u002Fsymptoms suggestive of SARS-CoV-2 infection or had recent known exposure to someone with SARS-CoV-2 infection, the subject must have a negative molecular (e.g., PCR) test, or 2 negative antigen test results at least 24 hours apart, to rule out SARS-CoV-2 infection. Subjects who do not meet SARS-CoV-2 infection eligibility criteria will be screen failed and may only rescreen after they meet the following SARS-CoV-2 infection viral clearance criteria:\n\n  * No signs\u002Fsymptoms suggestive of active SARS-CoV-2 infection\n  * Negative molecular (e.g., PCR) result or 2 negative antigen test results at least 24 hours apart\n* Screening 12-lead ECG showing a baseline QTcF \\>470 msec.",{"count":487,"type":21},100,[24],"The purpose of this study is to determine how effective and safe the combination of rituximab and epcoritamab is in treating patients with Follicular Lymphoma (FL) and who have not received other treatments for their lymphoma.\n\nThe names of the study drugs involved in this study are:\n\n* Rituximab (a type of monoclonal antibody therapy)\n* Epcoritamab (a T-cell bispecific antibody)",[28,491],"Low Grade Non-Hodgkin's Lymphoma, Adult",[438,28,493],"Low-grade Non-Hodgkin's Lymphoma","2026-05-19",{"date":496,"type":33},"2026-05-22",{"date":498,"type":33},"2023-06-21",{"date":147,"type":21},{"name":501,"class":73},"Reid Merryman, MD",6,{"id":504,"slug":505,"hasResults":12,"nctId":506,"briefTitle":507,"officialTitle":508,"acronym":4,"eligibilityCriteria":509,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":510,"targetDuration":4,"studyType":22,"phases":512,"briefSummary":513,"conditions":514,"keywords":515,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":519,"lastUpdatePostDateStruct":520,"startDateStruct":522,"completionDateStruct":524,"leadSponsor":526,"locationsCount":528},"100586140","phase-3-a-study-to-compare-the-efficacy-and-safety-of-golcadomide-in-combination-with-rituximab-golca--r-vs-investigators-choice-in-participants-with-relapsedrefractory-follicular-lymphoma-who-have-received-at-least-1-prior-line-of-systemic-therapy-golseek-4-100586140","NCT06911502","A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed\u002FRefractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)","A Phase 3, Multicenter, Randomized, Open Label Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) Vs Investigator's Choice in Participants With Relapsed\u002FRefractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy","Inclusion Criteria:\n\n\\- Participant has histologically confirmed FL (Grade 1, 2, 3a or classic FL) as assessed by local pathology. Adequate fresh tumor biopsy tissue or archived tumor biopsy from the latest relapse if available with corresponding pathology report for retrospective central pathology confirmation of relapse, is required. Evaluation from fine needle aspirate is not permitted.\n\n\\- Relapsed or refractory disease: i) Relapsed FL is defined as relapse after an initial response of CR or PR to the most recent prior therapy.\n\nii) Refractory FL is defined as best response of SD or PD or a response that lasted less than 6 months to the most recent prior therapy.\n\n* Eastern Cooperative Oncology Group (ECOG) 0-2 (ECOG 3 authorized if it is due to lymphoma and not comorbidities).\n* Participant must have positron emission tomography (PET)-positive disease with at least one PET-positive lesion and measurable disease on cross section imaging by CT, as defined by Lugano classification.\n* Participants with an indication for anti-lymphoma treatment as per investigator assessment based on modified Groupe d'Etude des Lymphomes Folliculaires (GELF) criteria.\n* Participant has received at least 1 or more prior lines of systemic therapy with one line consisting of a combination including an anti-CD20 monoclonal antibody (eg, rituximab, obinutuzumab) and an alkylating agent (eg, cyclophosphamide, bendamustine). Prior treatment with radiation therapy does not count as a line of therapy for eligibility.\n* Lab parameters:\n\n  i) Absolute neutrophil count (ANC) ≥ 1,000 cells\u002Fmm3 (1.0 x 109 \u002FL), ii) PLT count ≥ 75,000 cells\u002Fmm3 (75 x 109 \u002FL) iii) Hb ≥ 7.5 g\u002FdL\n* estimated glomerular filtration rate (eGFR) ≥ 30 ml\u002Fmin\u002F1.73m².\n* Serum aspartate transaminase (AST\u002FSGOT) or alanine transaminase (ALT\u002FSGPT) ≤ 2.5 x upper limit of normal (ULN). In case of documented liver involvement by lymphoma, ALT\u002FSGPT and AST\u002FSGOT must be ≤ 5.0× ULN.\n* Serum total bilirubin ≤ 1.5 × ULN (corresponding to mild dysfunction as per National Cancer Institute Organ Dysfunction Working Group \\[NCI ODWG\\] criteria). In case of documented liver involvement by lymphoma, serum total bilirubin must be ≤ 3.0 × ULN (corresponding to moderate dysfunction as per NCI ODWG criteria). For cases of Gilberts syndrome, serum total bilirubin≤ 5.0 × ULN.\n* Adequate cardiac function for participants receiving anthracycline-based chemotherapy, defined as left ventricular ejection fraction (LVEF) ≥ 45% as assessed by echocardiogram (ECHO) as standard of care or multi-gated acquisition scan (MUGA).\n\nExclusion Criteria:\n\n* Evidence or history of composite Diffuse large B-cell lymphoma (DLBCL) and FL or of transformed Non-Hodgkin Lymphoma (NHL), including history of prior large B-cell lymphomas (LBCL), or any other indolent lymphoma.\n* Follicular large cell as per 5th World Health Organization (WHO) sub-classification (grade 3b FL per WHO 4th classification) or duodenal-type FL.\n* Participant has any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the participant from compliantly participating in the study based on Investigator's judgment.\n* Participant has any condition that confounds the ability to interpret data from the study based on Investigator's or Sponsor's judgment.\n* Presence or history of central nervous system (CNS) involvement by lymphoma.\n* History of stroke or intracranial hemorrhage within 6 months prior to enrollment.\n* Deep venous thrombosis\u002FPulmonary embolism within 1 month prior to enrollment.\n* Participants with a history of progressive multifocal leukoencephalopathy.\n* Participant has any other subtype of lymphoma.\n* Participant has persistent diarrhea or malabsorption ≥ Grade 2 (NCI CTCAE v5.0), despite medical management.\n* History of another primary malignancy that has not been in remission for ≥ 3 years except for non-invasive malignancies.\n* Other protocol-defined Inclusion\u002FExclusion criteria apply.",{"count":511,"type":21},400,[25],"The study is designed as a multicenter, randomized, open label Phase 3 study to compare the efficacy and safety of golcadomide in combination with rituximab vs investigator's choice in participants with relapsed\u002Frefractory follicular lymphoma who have received at least one line of prior systemic therapy.",[28],[28,516,517,518],"Second Line Follicular Lymphoma","Third Line Follicular Lymphoma","Relapsed\u002Frefractory follicular lymphoma","2026-05-18",{"date":521,"type":33},"2026-05-20",{"date":523,"type":33},"2025-07-28",{"date":525,"type":21},"2030-07-31",{"name":527,"class":40},"Celgene",160,{"id":530,"slug":531,"hasResults":12,"nctId":532,"briefTitle":533,"officialTitle":534,"acronym":4,"eligibilityCriteria":535,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":536,"targetDuration":4,"studyType":22,"phases":538,"briefSummary":539,"conditions":540,"keywords":541,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":519,"lastUpdatePostDateStruct":545,"startDateStruct":546,"completionDateStruct":548,"leadSponsor":550,"locationsCount":551},"100469168","phase-2-a-study-of-mosunetuzumab-alone-or-with-zanubrutinib-in-people-with-follicular-lymphoma-100469168","NCT05389293","A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma","An Open-Label, Multicenter, Single-Arm, Sequential Phase-2 Study of Mosunetuzumab Alone or With Zanubrutinib for the Treatment of Patients With Newly Diagnosed Follicular Lymphoma in Need of Systemic Therapy","Inclusion Criteria:\n\n* Signed Informed Consent Form(s)\n* Ability to comply with all the study-related procedures, in the investigator's judgement\n* Age 18 years or older\n* ECOG performance Status of 0, 1, or 2 \\[Appendix 2\\]\n* Untreated histologically documented FL of grade 1, 2, or 3A\n* Stage II bulky (noncontiguous), III, or IV bulky or high burden disease \\[Appendix 3\\]\n* Need of systemic therapy as evidenced by at least one of the following criteria \\[also see Appendix 4\\]:\n\n  * Bulky disease defined as:\n  * Nodal or extranodal mass \\> 7cm in maximum diameter\n  * ≥ 3 nodal or extranodal sites each with a diameter ≥ 3 cm\n  * Presence of any of the following constitutional symptoms:\n  * Fever (\\>38C) of unclear etiology\n  * Night sweats\n  * Weight loss \\>10% within the prior 6 months\n  * Symptomatic splenomegaly\n  * Mass-related symptoms\n  * End-organ damage (e.g., elevated creatinine or elevated liver enzymes) that is clearly related to lymphomatous infiltration in the opinion of the investigator\n  * Any one of the following cytopenias due to lymphoma:\n  * Hemoglobin \\< 10g\u002FdL\n  * Platelets \\<100 x 10\\^9\u002FL\n  * Absolute neutrophil count (ANC) \\< 1.5 x 10\\^9\u002FL\n  * Pleural or peritoneal serous effusion (irrespective of cell content)\n  * Patients with absolute lymphocytosis ≥5,000 cells\u002FµL in the peripheral blood may be allowed to participate after discussion with the study PI\n* Must be considered as a potential candidate for chemoimmunotherapy in the judgement of the treating physician\n* Must have at least one bi-dimensionally measurable lesion (\\>1.5 cm in its largest dimension for nodal lesions, or \\>1.0 cm in its largest dimension for extranodal lesions by computerized tomography \\[CT\\] scan or MRI)\n* Agreement to provide tumor samples as follows:\n\n  * Agreement to undergo biopsy of a safely accessible tumor site per investigator determination prior to the first dose of mosunetuzumab.\n  * Agreement to undergo repeat biopsy of the same tumor site, if safely accessible, or a different safely accessible tumor site, per investigator determination, 14 to 21 days after the first dose of mosunetuzumab.\n  * Patients who are unable or unwilling to undergo either biopsy procedure may be allowed to participate in, or continue with, the study without any penalization after confirmation from the PI. Inability to undergo a new pre-treatment or an on-treatment biopsy are not considered protocol violations.\n* Adequate hepatic function as follows: aspartate transaminase (AST) and alanine transaminase (ALT) levels ≤3 x upper limit of normal (ULN); total bilirubin level ≤1.5 x ULN (except with documented history of Gilbert syndrome)\n* Adequate bone marrow function as follows:\n\n  * Platelet count ≥75 x 10\\^9\u002FL without transfusion within 14 days prior to first dose of mosunetuzumab;\n  * ANC ≥1 x 10\\^9\u002FL\n  * Hemoglobin level ≥9 g\u002FdL without transfusion within 14 days prior to the first dose of mosunetuzumab\n  * Patients who do not meet criteria for bone marrow function due to marrow involvement of lymphoma and\u002For other disease-related cytopenias (e.g., immune thrombocytopenia) may be enrolled into the study after discussion with, and confirmation by the PI.\n* Serum creatinine ≤ULN or estimated creatinine clearance ≥ 45 mL\u002Fmin by Cockcroft-Gault method \\[see Appendix 5\\] or other institutional standard methods (e.g., based on nuclear medicine renal scan)\n* For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of ≤1% per year, and agreement to refrain from donating eggs, during the treatment period and for at least 3 months after the last dose of mosunetuzumab, and 3 months after the last dose of tocilizumab (if applicable), whichever is longer.\n\n  * A woman is considered to be of childbearing potential if she is post-menarcheal, has not reached a post-menopausal state (≥12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (removal of ovaries and\u002For uterus).\n  * Examples of contraceptive methods with a failure rate of ≤1% per year include bilateral tubal ligation, male sterilization, established proper use of hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices.Hormonal contraception methods must be supplemented by a barrier method.\n  * The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or post-ovulation methods) and withdrawal are not acceptable methods of contraception.\n* For men: agreement to remain abstinent (refrain from heterosexual intercourse), or use a condom, and agreement to refrain from donating sperm, as defined below:\n\n  * With female partners of childbearing potential or pregnant female partners, men must remain abstinent or use a condom during the treatment period and for at least 60 days after the last dose of mosunetuzumab and tocilizumab (if applicable) to avoid exposing the embryo. Men must refrain from donating sperm during this same period.\n  * The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence and withdrawal are not acceptable methods of contraception.\n\nExclusion Criteria:\n\n* Inability to comply with all the study-related procedures, in the investigator's judgement.\n* FL grade 3B or transformed FL\n* Patients not meeting criteria for systemic therapy as outlined in section 6.1 and Appendix 4\n* Patients unfit for chemoimmunotherapy for reasons including, but not limited to, advanced age and medical comorbidities\n* FL presenting with isolated extra-nodal localizations, such as duodenal FL, cutaneous FL or FL of the testis\n* Pediatric FL\n* Prior anti-lymphoma therapy\n* Prior solid organ transplantation\n* Prior allogeneic stem cell transplantation within 5 years of FL diagnosis. Previously transplanted patients must be off all GVHD-related prophylaxis in order to be considered eligible.\n* Current or prior central nervous system (CNS) lymphoma\n* Current or past history of significant CNS disease, such as stroke, epilepsy, CNS vasculitis, or neurodegenerative disease\n\n  * Patients with a history of stroke who have not experienced a stroke or transient ischemic attack in the past 2 years and have no residual neurologic deficits as judged by the investigator are allowed\n  * Patients with a history of epilepsy who have had no seizures in the past 2 years while not receiving any anti-epileptic medications are allowed\n* Significant cardiovascular disease such as New York Heart Association Class III or IV cardiac disease \\[see Appendix 6\\], myocardial infarction within the last 6 months, unstable arrhythmias, or unstable angina\n* Significant active pulmonary disease (e.g., bronchospasm or obstructive pulmonary disease)\n* Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at study enrollment, or any major episode of infection requiring treatment with IV antibiotics or hospitalization (relating to the completion of the course of antibiotics) within 4 weeks prior to first mosunetuzumab administration\n* Known or suspected chronic active Epstein-Barr Virus infection\n* Serologic or PCR test results indicating acute or chronic HBV infection\n\n  ° Patients whose HBV infection status cannot be determined by serologic test results (www.cdc.gov\u002Fhepatitis\u002Fhbv\u002Fpdfs\u002Fserologicchartv8.pdf) must be negative for HBV by PCR to be eligible for study participation.\n* Acute or chronic HCV infection\n\n  ° Patients who are positive for HCV antibody must be negative for HCV by PCR to be eligible for study participation.\n* Serologic test results indicating HIV infection\n* Administration of a live, attenuated vaccine within 4 weeks before first dose of study treatment or anticipation that such a live attenuated vaccine will be required during the study\n\n  * Patients must not receive live, attenuated vaccines (e.g., FluMist®) while receiving study treatment or after the last dose until B-cell recovery to the normal ranges. Killed vaccines or toxoids should be given at least 4 weeks prior to the first dose of study treatment to allow development of sufficient immunity.\n  * Inactivated influenza vaccination during influenza season and the COVID-19 vaccination at any time are allowed. Please see section 10.3.2 (permitted concomitant therapy) for additional guidance on SARS-CoV-2 vaccine administration and timing\n  * Investigators should review the vaccination status of potential study patients being considered for this study and follow the U.S. Centers for Disease Control and Prevention guidelines for adult vaccination with any other non-live vaccines intended to prevent infectious diseases prior to study.\n* Pregnant, lactating, or intending to become pregnant during the study or within 3 months after the last dose of mosunetuzumab and 3 months after the last dose of tocilizumab (if applicable)\n\n  ° Women who are not postmenopausal (≥12 months of non-therapy-induced amenorrhea) or surgically sterile (removal of ovaries and\u002For uterus) must have a negative serum pregnancy test result within 14 days prior to initiation of study drug. If a serum pregnancy test has not been performed within 14 days prior to receiving first study treatment, a negative urine pregnancy test result (performed within 7 days prior to study treatment) must be available.\n* Radiation therapy, unless utilized for the sole purpose of acutely controlling symptomatic disease during the screening period. In this case, at least 2 weeks should lapse between the last radiation dose and the first mosunetuzumab administration and the patient must still have measurable disease outside the field of radiation prior to initiation of the study drug\n* Recent major surgery within 4 weeks prior to first mosunetuzumab administration, except protocol-mandated procedures (e.g., tumor biopsies and bone marrow biopsies)\n* History of autoimmune disease, including, but not limited to myocarditis, pneumonitis, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis\n\n  * Patients with a remote history of, or well-controlled autoimmune disease, may be eligible to enroll after discussion with and confirmation by the PI.\n  * Patients with controlled Type 1 diabetes mellitus who are on an insulin regimen are eligible for the study.\n  * Patients with a history of autoimmune-related hypothyroidism on a stable dose of thyroid replacement hormone may be eligible for this study.\n  * Patients with a history of disease-related immune thrombocytopenic purpura or autoimmune hemolytic anemia may be eligible for this study.\n  * Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis are excluded) are eligible for the study provided all of following conditions are met:\n  * Rash must cover \\<10% of body surface area\n  * Disease is well controlled at baseline and requires only low-potency topical corticosteroids\n  * No occurrence of acute exacerbations of the underlying condition requiring psoralen plus ultraviolet A radiation, methotrexate, retinoids, biologic agents, oral calcineurin inhibitors, or high potency or oral corticosteroids within the previous 12 months.\n* History of known HLH or suspected HLH in the opinion of the investigator\n* History of confirmed progressive multifocal leukoencephalopathy (PML)\n* History of severe allergic or anaphylactic reactions to monoclonal antibody therapy (or recombinant antibody-related fusion proteins)\n* History of other malignancy, except:\n\n  * Curatively treated basal cell carcinoma, squamous cell carcinoma of the skin, in situ cervical carcinoma, in situ prostatic neoplasia.\n  * A malignancy treated with curative intent and in remission for at least 2 years prior to the first mosunetuzumab administration\n* Receipt of systemic immunosuppressive medications (including but not limited to cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor agents) with the exception of corticosteroid treatment ≤10 mg\u002Fday prednisone or equivalent within 2 weeks prior to first dose of mosunetuzumab. The following is permitted:\n\n  * The use of up to 12 mg\u002Fday dexamethasone for up to 3 days as antiemetic therapy\n  * The use of up to 1mg\u002Fkg of prednisone or equivalent for ≤7 days to control B symptoms\n  * The use of inhaled corticosteroids\n  * The use of mineralocorticoids for management of orthostatic hypotension\n  * The use of physiologic doses of corticosteroids for management of adrenal insufficiency\n  * The use of premedication corticosteroids prior to undergoing contrast-enhanced imaging studies, in patients who are allergic to contrast agents\n* History of illicit drug or alcohol abuse within 12 months prior to screening, in the investigator's judgment\n* Any serious medical condition or abnormality in clinical laboratory tests that, in the investigator's or PI's judgment, precludes the patient's safe participation in and completion of the study, or which could affect compliance with the protocol or interpretation of results\n\nCohort 2 only:\n\n* Requirement fors ongoing treatment with a strong CYP3A inhibitor or inducer (see section 15.2.3.2)\n* History of severe bleeding disorder such as hemophilia A, hemophilia B, von Willebrand disease, or history of spontaneous bleeding requiring blood transfusion or other medical intervention.\n* History of intracranial hemorrhage ≤ 180 days before the first dose of study treatment\n* Inability to swallow capsules clinically significant or gastrointestinal dysfunction such as demonstrated malabsorption syndrome, resection of the stomach or small bowel, bariatric surgery, symptomatic inflammatory bowel disease, or bowel obstruction.\n* Consumption of one or more of the following within 3 days prior to the first dose of zanubrutinib:\n\n  * Grapefruit or grapefruit products\n  * Seville oranges, including marmalade containing Seville oranges\n  * Star fruit (carambola)",{"count":537,"type":21},152,[24],"The purpose of this study is to find out if mosunetuzumab is an effective treatment in people with follicular lymphoma that was recently diagnosed and have not yet received any treatments for their disease.",[28,55],[542,28,55,543,544],"Mosunetuzumab","Memorial Sloan Kettering Cancer Center","22-100",{"date":494,"type":33},{"date":547,"type":33},"2022-05-27",{"date":549,"type":21},"2026-12",{"name":543,"class":73},9,{"id":553,"slug":554,"hasResults":12,"nctId":555,"briefTitle":556,"officialTitle":557,"acronym":558,"eligibilityCriteria":559,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":560,"targetDuration":4,"studyType":22,"phases":562,"briefSummary":563,"conditions":564,"keywords":565,"overallStatus":469,"whyStopped":4,"lastUpdateSubmitDate":569,"lastUpdatePostDateStruct":570,"startDateStruct":572,"completionDateStruct":574,"leadSponsor":576,"locationsCount":422},"100640682","phase-2-a-exploratory-study-on-untreated-follicular-lymphoma-with-orelabrutinib-tafasitamab-and-lenalidomide-100640682","NCT07585747","A Exploratory Study on Untreated Follicular Lymphoma With Orelabrutinib, Tafasitamab, and Lenalidomide","A Multicenter Exploratory Clinical Study on the Treatment of Untreated Follicular Lymphoma With Orelabrutinib, Tafasitamab, and Lenalidomide","CUREMZL002","Inclusion Criteria:\n\n1. Age \\> 18 years, regardless of gender;\n2. Newly diagnosed patients with follicular lymphoma (Grade 1, 2, or 3a) confirmed histologicallyaccording to the World Health Organization (WHO) classification of diseases;\n3. Deemed by the investigator to have an indication for treatment and require therapy;\n4. ECOG performance status score of 0-2;\n5. Laboratory tests meeting the following criteria:\n\n   1. Bone marrow hematopoietic function is essentially normal: WBC 3.5x10\\^9\u002FL, ANC \\> 1.0x10\\^9\u002FL, PLT \\> 75x10\\^9\u002FL, Hb \\> 80 g\u002FL;\n   2. Liver function: AST\u002FALT s 2xULN, TBILI s 2xULN;\n   3. Renal function: Creatinine clearance rate \\> 50 ml\u002Fmin;6. Presence of at least one measurable lesion: Lymph node lesion with a long diameter \\> 1.5 cm orextranodal lesion with a long diameter \\> 1.0 cm as shown by PET\u002FCT, CT, or MRl, or a lesion \\> 2cm assessed by clinical examination;\n\n7\\. Ability to provide written informed consent.\n\nExclusion Criteria:\n\n1. Women with a positive serum pregnancy test or who are breastfeeding;\n2. Patients with lymphoma involving the central nervous system (CNS);\n3. Clinically significant heart disease, including unstable angina, acute myocardial infarction within6 months prior to randomization, congestive heart failure with New York Heart Association(NYHA) functional class IIl or IV, or left ventricular ejection fraction \\\u003C50%;\n4. Patients with grade \\>2 neuropathy;\n5. Patients with active hepatitis B (HBV, hepatitis C (HCV, or other acquired\u002Fcongenitalimmunodeficiency diseases;\n6. Patients with severe active infections requiring systemic antibiotic treatment;\n7. Patients with a history of severe neurological or psychiatric disorders that impair trialparticipation, including dementia, epilepsy, severe depression, and mania;8. Drug abuse, or medical, psychological, or social conditions that may interfere with studyparticipation or result evaluation;\n\n9\\. Patients deemed ineligible by the investigator.",{"count":561,"type":21},27,[24],"Evaluate the efficacy and safety of orelabrutinib, tafasitamab, and lenalidomide in the first-line treatment of patients with follicular lymphoma.",[28],[566,567,568],"lenalidomide","tafasitamab","orelabrutinib","2026-05-10",{"date":571,"type":33},"2026-05-14",{"date":573,"type":21},"2026-04-15",{"date":575,"type":21},"2030-12-31",{"name":300,"class":73},{"id":578,"slug":579,"hasResults":12,"nctId":580,"briefTitle":581,"officialTitle":582,"acronym":583,"eligibilityCriteria":584,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":585,"enrollmentInfo":586,"targetDuration":4,"studyType":22,"phases":588,"briefSummary":589,"conditions":590,"keywords":591,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":569,"lastUpdatePostDateStruct":594,"startDateStruct":596,"completionDateStruct":598,"leadSponsor":600,"locationsCount":301},"100615941","phase-2-zanubrutinib-obinutuzumab-combined-with-lenalidomide-zgr-for-the-treatment-of-untreated-follicular-lymphoma-100615941","NCT07299149","Zanubrutinib, Obinutuzumab Combined With Lenalidomide (ZGR) for the Treatment of Untreated Follicular Lymphoma","A Prospective, Open-label, Single-arm Multicenter Clinical Study of Zanubrutinib, Obinutuzumab, and Lenalidomide (ZGR) in the Treatment of Untreated Follicular Lymphoma","ZGR in TN FL","Inclusion Criteria:\n\n* Gender: No restrictions; age ≥18 years.\n* Diagnosis: Histologically confirmed CD20-positive follicular lymphoma (FL), Grade 1, 2, or 3A, per 2016 WHO classification. All patients must provide sufficient archived or fresh tumor tissue samples for immunohistochemical (IHC) analysis.\n* Disease Stage \\& Treatment Need:\n* Stage III or IV disease, or Stage II with bulky disease, meeting at least one of the following criteria:\n* a) Bulky disease: Lymph node or extranodal (excluding spleen) mass with maximum diameter ≥7 cm.\n* b) Local symptoms or organ dysfunction due to progressive lymphadenopathy or extranodal tumor mass.\n* c) B symptoms (fever, night sweats, or unintentional weight loss \\>10% of body weight within ≤6 months).\n* d) Symptomatic extranodal involvement (e.g., pleural\u002Fperitoneal effusion).\n* e) Cytopenias due to bone marrow infiltration (hemoglobin \\\u003C10 g\u002FdL, absolute neutrophil count \\[ANC\\] \\\u003C1.0×10⁹\u002FL, platelets \\\u003C100×10⁹\u002FL).\n* f) Involvement of ≥3 lymph nodes, each ≥3 cm in diameter.\n* g) Symptomatic splenomegaly.\n* Prior Therapy: No prior systemic therapy for FL.\n* ECOG Performance Status: ≤2.\n* Measurable Disease: At least one measurable lesion (\\>2 cm in longest diameter by CT\u002FMRI).\n* Life Expectancy: ≥6 months.\n* Adequate Organ Function:\n* a) ANC ≥1.0×10⁹\u002FL (without growth factor support).\n* b) Platelets ≥50×10⁹\u002FL (untransfused within 7 days).\n* c) Total bilirubin (TBIL) ≤1.5×ULN.\n* d) ALT\u002FAST ≤3×ULN.\n* e) Creatinine clearance ≥30 mL\u002Fmin (calculated by modified Cockcroft-Gault formula).\n* Contraception: Men and women of childbearing potential must agree to use highly effective contraception during the study and for 4 weeks after treatment discontinuation.\n* Informed Consent: Patients must voluntarily participate and sign informed consent forms (ICF).\n\nExclusion Criteria:\n\n* Patients meeting any of the following criteria will be excluded from this study:\n* Histologic evidence of central nervous system (CNS) lymphoma, leptomeningeal lymphoma, or transformation to high-grade lymphoma (e.g., diffuse large B-cell lymphoma, DLBCL).\n* Grade 3B follicular lymphoma (FL) or transformed FL.\n* Ann Arbor Stage I FL.\n* Prior history of malignancy, unless the patient has been disease-free for ≥5 years and the treating physician deems the risk of recurrence low (exceptions: non-melanoma skin cancer, cured localized prostate cancer, carcinoma in situ of the cervix, or squamous intraepithelial lesions on PAP smear).\n* Use of any investigational drugs, antibiotics, or participation in another interventional clinical trial within 4 weeks prior to enrollment.\n* Major surgery (excluding lymph node biopsy) within 14 days before enrollment or anticipated need for major surgery during the study.\n* Prior treatment with zanubrutinib, obinutuzumab, or lenalidomide.\n* Immunodeficiency or autoimmune disease history, or chronic systemic steroid therapy (\\>10 mg\u002Fday prednisone equivalent) or immunosuppressive therapy within 7 days before enrollment.\n* Severe hepatic dysfunction (including severe jaundice, hepatic encephalopathy, refractory ascites, or hepatorenal syndrome), cachexia, or multi-organ failure with renal impairment.\n* Clinically significant cardiovascular abnormalities:\n* NYHA Class III\u002FIV heart failure\n* Myocardial infarction within 6 months before enrollment, Malignant arrhythmias (including QTc ≥480 ms), Uncontrolled hypertension (Systolic blood pressure (SBP) ≥150 mmHg and diastolic blood pressure (DBP) ≥100 mmHg), Unstable angina.\n\nActive infections:\n\n* HIV, active hepatitis B\u002FC infection (HBV DNA ≥2000 IU\u002FmL or HCV RNA detectable)\n* Uncontrolled systemic infections.\n* Bleeding disorders or coagulation abnormalities, or thrombotic events within 3 months.\n* Severe hypersensitivity to the active ingredients or excipients of the study drugs.\n* Pregnancy, lactation, or unwillingness to use effective contraception in women of childbearing potential.\n* Other conditions deemed unsuitable by the investigator.","90 Years",{"count":587,"type":21},34,[24],"This study is planned to prospectively evaluates the efficacy and safety of the zanubrutinib, obinutuzumab, and lenalidomide (ZGR) combination regimen in treatment-naïve follicular lymphoma (FL) patients in a Chinese population.",[28],[592,593,443,566],"follicular lymphoma","zanubrutinib",{"date":595,"type":33},"2026-05-13",{"date":597,"type":33},"2025-12-25",{"date":599,"type":21},"2030-12-25",{"name":300,"class":73},{"id":602,"slug":603,"hasResults":12,"nctId":604,"briefTitle":605,"officialTitle":606,"acronym":4,"eligibilityCriteria":607,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":608,"enrollmentInfo":609,"targetDuration":4,"studyType":22,"phases":610,"briefSummary":611,"conditions":612,"keywords":617,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":620,"lastUpdatePostDateStruct":621,"startDateStruct":623,"completionDateStruct":625,"leadSponsor":627,"locationsCount":74},"100581617","phase-2-cd70-targeted-immunopet-imaging-of-malignant-cancers-100581617","NCT06852638","CD70-targeted immunoPET Imaging of Malignant Cancers","CD70-targeted PET\u002F CT in the Diagnosis of Malignant Cancers","Inclusion Criteria:\n\n* Aged 18-80 year-old and of either sex；\n* Histologically confirmed diagnosis of renal cancer (especially ccRCC)\u002Flymphoma\u002FNPC or suspected renal cancer\u002Flymphoma\u002FNPC by diagnostic imaging;\n* Capable of giving signed informed consent, including compliance with the requirements and restrictions in the informed consent form (ICF) and this protocol.\n\nExclusion Criteria:\n\n* Pregnancy；\n* Severe hepatic and renal insufficiency;\n* Allergic to single-domain antibody radiopharmaceuticals.","80 Years",{"count":84,"type":21},[24],"This study aims to determine the value of cluster of differentiation (CD70)-targeted immuno-positron emission tomography\u002Fcomputed tomography (immunoPET\u002FCT) imaging for diagnosing human malignancies, including renal cell carcinoma (particularly clear cell renal cell carcinoma), lymphoma, and nasopharyngeal carcinoma (NPC), among others.",[613,614,55,615,28,203,616],"Renal Cancer","Renal Clear Cell Carcinoma","Lymphoma, Large B-Cell, Diffuse","Nasopharyngeal Carcinoma",[618,619,613,55,616],"The cluster of differentiation (CD70)","ImmunoPET","2026-05-07",{"date":622,"type":33},"2026-05-12",{"date":624,"type":33},"2024-12-23",{"date":626,"type":21},"2026-12-23",{"name":628,"class":73},"RenJi Hospital",{"id":630,"slug":631,"hasResults":12,"nctId":632,"briefTitle":633,"officialTitle":633,"acronym":4,"eligibilityCriteria":634,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":635,"targetDuration":4,"studyType":22,"phases":637,"briefSummary":638,"conditions":639,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":640,"lastUpdatePostDateStruct":641,"startDateStruct":643,"completionDateStruct":645,"leadSponsor":647,"locationsCount":74},"100519421","phase-2-a-phase-ii-study-of-axicabtagene-ciloleucel-an-anti-cd19-chimeric-antigen-receptor-car-tcell-therapy-in-combination-with-radiotherapy-rt-in-relapsedrefractory-follicular-lymphoma-100519421","NCT06043323","A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed\u002FRefractory Follicular Lymphoma","Inclusion Criteria:\n\nEligible subjects will be considered for inclusion if they meet all of the following criteria:\n\n* Men and women 18 years of age or older\n* Histologically proven FL (Grade 1-3A) on most recent biopsy, history of transformed follicular lymphoma permitted at clinician discretion)\n* Patients with follicular lymphoma must have disease that has relapsed or is refractory to 2 or more prior lines of systemic therapy\n* (ECOG) performance status of 0-2\n* Medically appropriate for CAR-T cell therapy: adequate organ function CrCL \\>\u002F= 45 mL\u002Fmin\u002Fm2, hemoglobin level ≥ 8 g\u002Fdl, serum alanine aminotransferase (ALT)\u002Faspartate aminotransferase (AST) levels ≤ 2.5 × upper limit of normal (ULN) or ≤ 5 x ULN if documented liver involvement, baseline oxygen saturation levels (SpO2) ≥92% on room air\n* Have at least 1 measurable lesion on imaging, defined as a lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) and ≥1 cm on CT, MRI, or clinical exam.\n* Prior radiation therapy is permitted provided normal tissue tolerance is not exceeded\n* Female of child-bearing potential (FOCBP, defined below) must have a negative pregnancy test within 1 week of simulation for RT\n* Ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n* History of other (non B-cell lymphoma) invasive malignancy requiring active therapy (systemic therapy, radiation, or surgery) within the past 3 years, excluding non-melanomatous skin cancer\n* Women of childbearing potential who are pregnant\n* Women who are breastfeeding and unwilling to discontinue prior to lymphodepleting chemotherapy and for 12 months following lymphodepleting chemotherapy and CAR-T cell infusion\n* Urgent need for bridging chemotherapy or rituximab between apheresis and CAR T cell product infusion (steroids permitted)\n* Additional RT would exceed standard organ at risk constraints\n* History of severe, immediate hypersensitivity reaction attributed to aminoglycosides\n* Uncontrolled fungal, bacterial, or viral infection requiring intravenous antimicrobials for management. Urinary tract infection and uncomplicated bacterial pharyngitis is permitted if responding to active treatment. Recent COVID19 infection is permitted if patient is deemed medically stable for CAR-T cell therapy.",{"count":636,"type":21},20,[24],"To learn about the safety of a drug called axicabtagene ciloleucel given in combination with radiation therapy to patients with relapsed\u002Frefractory FL.",[28],"2026-05-04",{"date":642,"type":33},"2026-05-06",{"date":644,"type":33},"2024-01-08",{"date":646,"type":21},"2028-09-01",{"name":648,"class":73},"M.D. Anderson Cancer Center",{"id":650,"slug":651,"hasResults":12,"nctId":652,"briefTitle":653,"officialTitle":654,"acronym":4,"eligibilityCriteria":655,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":656,"targetDuration":4,"studyType":22,"phases":658,"briefSummary":659,"conditions":660,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":662,"lastUpdatePostDateStruct":663,"startDateStruct":665,"completionDateStruct":667,"leadSponsor":669,"locationsCount":671},"100438464","phase-2-orelabrutinib-plus-rituximab-followed-by-maintenance-with-orelabrutinib-for-relapsed-and-refractory-follicular-lymphomarr-fl-100438464","NCT04989621","Orelabrutinib Plus Rituximab Followed by Maintenance With Orelabrutinib for Relapsed and Refractory Follicular Lymphoma(RR FL)","Orelabrutinib Plus Rituximab Followed by Maintenance With Orelabrutinib for Relapsed and Refractory Follicular Lymphoma(RR FL) ：a Single Arm, Open Label, Multi-center Phase II Study","Inclusion Criteria:\n\n* Histologically confirmed grade 1, 2, or 3A FL;\n* Patients received prior anti-lymphoma treatment;\n* At least one evaluable lesion according to 2014 Lugano criteria;\n* Age 18 years or older;\n* Eastern Cooperative Oncology Group (ECOG) of 0-2;\n* Life expectancy \\> 3 months;\n* Able to participate in all required study procedures;\n* Proper functioning of the major organs:\n\nExclusion Criteria:\n\n* Patients who required warfarin or had a history of stroke or intracranial hemorrhage within 6 months, active transformed disease;\n* Histological transformation of follicular lymphoma;\n* Known central nervous system lymphoma;\n* Received a prior allogeneic hematopoietic stem cell transplant. Prior autologous hematopoietic stem cell transplant is allowed;\n* Subjects who have received prior treatment with ibrutinib, or other BTK inhibitors;\n* Uncontrolled active infection, with the exception of tumor-related B symptom fever;\n* Prior nitrosoureas within 6 weeks, chemotherapy within 3 weeks, therapeutic anticancer antibodies within 4 weeks, radio- or toxin-immunoconjugates within 10 weeks, radiation therapy or other investigational agents within 3 weeks, or major surgery within 4 weeks of first dose of study drug;\n* Subjects who progressed or become refractory while on treatment with PI3K inhibitors are excluded. However, subjects who were responding to PI3K inhibitors, but had treatment discontinued due to toxicity, are eligible;\n* Patients require treatment with strong CYP3A inhibitors;\n* Clinically significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of Screening;\n* Patients with active hepatitis B or active hepatitis C. Patients who are positive for hepatitis B Surface Antigen (HBsAg) or hepatitis C Virus (HCV) antibodies at screening stage must pass further detection of hepatitis B Virus (HBV) DNA (no more than 1000 IU\u002FmL) and HCV RNA (no more than the lower limit of the detection method) in the row. Hepatitis B carriers, stable hepatitis B (DNA titer should not be higher than 1000 IU\u002FmL) after drug treatment, and cured hepatitis C patients can be enrolled in the group;",{"count":657,"type":21},32,[24],"This phase 2 trial studies the efficacy and safety of orelabrutinib plus rituximab followed by maintenance with orelabrutinib for relapsed and refractory follicular lymphoma(RR FL)",[28,661],"Relapsed and Refractory Follicular Lymphoma","2026-04-21",{"date":664,"type":33},"2026-04-23",{"date":666,"type":33},"2021-08-01",{"date":668,"type":21},"2028-08",{"name":670,"class":73},"Sun Yat-sen University",3,{"id":673,"slug":674,"hasResults":12,"nctId":675,"briefTitle":676,"officialTitle":677,"acronym":4,"eligibilityCriteria":678,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":679,"targetDuration":4,"studyType":22,"phases":681,"briefSummary":682,"conditions":683,"keywords":687,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":694,"lastUpdatePostDateStruct":695,"startDateStruct":696,"completionDateStruct":698,"leadSponsor":700,"locationsCount":702},"100461905","phase-1-treatment-of-chinese-participants-with-b-cell-malignancies-with-bgb-16673-a-bruton-tyrosine-kinase-targeted-protein-degrader-100461905","NCT05294731","Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader","A Phase 1\u002F2, Open-Label, Dose-Escalation and Expansion Study of the Bruton Tyrosine Kinase-Targeted Protein-Degrader BGB-16673 in Chinese Patients With B-Cell Malignancies","Key Inclusion Criteria\n\n1. Provision of signed and dated written informed consent prior to any study\n2. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2\n3. Adequate organ function of coagulation function, liver function, renal function and pancreatic function and measure disease per disease-specific response criteria\n4. Phase 1: Confirmed diagnosis of R\u002FR Marginal Zone Lymphoma (MZL), Follicular Lymphoma (grade 1-3a), Waldenström Macroglobulinemia (WM), non-germinal center B-cell (non-GCB) diffuse large B-cell lymphoma (DLBCL), Richter's transformation to DLBCL, MCL, or CLL\u002FSLL\n5. Phase 2: Confirmed diagnosis of MCL, or CLL\u002FSLL\n6. Highly effective method of birth control during study treatment period, and for at least 90 days after the last dose of the study drug\n\nKey Exclusion Criteria\n\n1. Prior malignancy (other than the disease under study) within the past 2 years, except for curatively treated basal or squamous skin cancer, superficial bladder cancer, carcinoma in situ of the cervix or breast, or localized Gleason score ≤ 6 prostate cancer\n2. Require ongoing systemic treatment for any other malignancy or systemic corticosteroid treatment\n3. Receiving treatment with a strong CYP3A inhibitor or inducer ≤ 14 days before the first dose of BGB-16673, or proton-pump inhibitors ≤ 5 days before the first dose of BGB-16673.\n4. Current or history of central nervous involvement\n5. Prior autologous stem cell transplant unless ≥ 3 months after transplant, prior chimeric cell therapy unless ≥ 6 months after cell infusion, prior allogeneic stem cell transplant ≤ 6 months before the first dose of the study drug\n\nNote: Other protocol defined Inclusion\u002FExclusion criteria may apply",{"count":680,"type":21},146,[137,24],"This study aims to explore the recommended phase 2 dose and evaluate the safety, tolerability and preliminary antitumor activity of BGB-16673 monotherapy at the recommended Phase 2 dose for the selected B-cell malignancy expansion cohorts",[200,201,203,684,202,58,28,685,686],"Chronic Lymphocytic Leukemia\u002FSmall Lymphocytic Lymphoma","DLBCL Unclassifiable","Richter's Transformation",[200,688,439,689,686,690,691,692,693],"MZL","DLBCL","CDAC","BTK","degrader","BGB-16673","2026-04-14",{"date":145,"type":33},{"date":697,"type":33},"2022-05-06",{"date":699,"type":21},"2029-01-31",{"name":701,"class":40},"BeiGene",29]